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INTRODUCTION 
Theophylline is a dimethylated xanthine similar in structure to caffeine which is 
commonly found in tea, coffee and cola beverages (Hendeles and Weinberger, 1983; 
Rall, 1985). Clinically, its most important pharmacological action is the ability to 
relax bronchial smooth muscle throughout the bronchial tree (Persson, 1986). This 
effect has found extensive use in the treatment of asthma with the drug being 
recommended as the first line agent for chronic asthma (la/rate et ai, 1986). 
The observation that both beneficial effects as well as toxicity correlate with serum 
concentrations and that the drug displays a narrow therapeutic window (Finn et aI, 
1981; Hendeles and Matthay, 1986) has resulted in the recommendation that 
theophylline dosing be guided by serum concentration measurements (Hendeles and 
Weinberger, 1980; Whiting et aI, 1984; Fitzpatrick and Moss-Barclay, 1985; Barlow et 
aI, 1988). However, this recommendation appears to have been largely ignored 
locally. In 1986, one of the first local Therapeutic Drug Monitoring Clinics for 
theophylline was established at R K Khan Provincial Hospital in Chatsworth, 
Durban. Preliminary results from this clinic confirmed the widespread use of 
standard theophylline dosing regimens and revealed that 68% (n = 44) of patients 
given these regimens had serum theophylline concentrations below the generally 
accepted therapeutic range (Pillai and Miller, 1988). 
Previous studies have assessed the influence of Therapeutic Drug Monitoring 
programmes in terms of the attainment of 'therapeutic' serum concentrations 
(Whiting et aI, 1984; Fitzpatrick and Moss-Barclay, 1985). This approach has been 
criticised and it has been recommended that clinical assessment should be the 
criterion. The purpose of this study was to investigate the influence of serum 
concentration monitoring on theophylline utilisation at the R K Khan Hospital in 
terms of clinical control of asthma symptoms. 
A secondary purpose of this study was to determine population pharmacokinetic 
parameters in Indian patients. In order to interpret the serum concentrations and 
make recommendations on dosage design for individual patients, the Bayesian 
technique of drug dose optimisation is used (Sheiner et aI, 1972). This technique has 
been shown to be accurate, precise and easy to use (Sheiner and Beal, 1982; Hurley 
1 
and McNeil, 1988) particularly with currently available computer software. It has 
been emphasised, however, that for satisfactory performance of this technique, good 
initial estimates of the population parameter distributions are important (Whiting et 
aI, 1986). Since this information is not available for the Indian population this study 
was undertaken. A knowledge of population pharmacokinetics can help one to 
choose initial dosage, to modify dosage appropriately in response to observed drug 
levels, to make rational decisions regarding drug regulatory requirements and to 
investigate and elucidate certain research questions in pharmacokinetics (Sheiner, 
1984). The NONMEM approach (Sheiner et aI, 1972; 1977), currently the most 
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Chapter One 
Theophylline - Pharmaceutical Chemistry, Mechanism of Action, Pharmacology, 
Toxicity and Pharmacokinetics. 
1.1 PHARMACEUTICAL CHEMISTRY 
1.1.1 Structure 
Theophylline 
Fig. 1 - Structure of 1,3-dimethylxanthine (theophylline) 
Theophylline is a dimethylated xanthine similar In structure to caffeine 
(1,3,7-trimethylxanthine) and theobromine (3,7-dimethylxanthine). These alkaloids 
occur in plants widely distributed throughout the world. They are commonly found 
in coffee, tea, cola beverages and chocolate (Hendeles and Weinberger, 1983; Rall, 
1985). 
1.1.2 Solubility 
Theophylline is poorly soluble in water (8 mg/ml at 25°C) and therefore various 
complexes (so-called 'salts') have been developed, with a view to improving the 
solubility and absorption of the drug. At physiological pH, theophylline is a weak 
5 
base (pKa = 8.8) and only slightly ionised and therefore incapable of existing as a 
salt. Salts of theophylline with a base e.g. ethylenediamine can only be formed at 
much higher pH values due to a tautomeric shift in hydrogen. Therefore, at 
physiological pH these so-called 'salts' are actually mixtures of theophylline and 
base - the base having no useful pharmacological activity (Hendeles and Weinberger, 
1983) and may in fact be implicated in adverse effects (Elias and Levinson, 1981). 
The absorption of the methylxanthines has been shown to relate more to their 
lipophilic characteristics than to water solubility. The formation of complexes of 
theophylline with the ultimate aim of increasing absorption is therefore irrational 
(HendeZes and Weinberger, 1983). 
In addition, the contribution of the base to the mass of the dosage form complicates 
the calculation of appropriate doses during therapy. In view of these factors all 
dosing and labelling of theophylline should be in terms of the content of anhydrous 
theophylline in the preparation. At present this is not a legal labelling requirement 
in South Africa. This is unfortunate if one considers the potential for dangerous 
dosage errors. For example, a change in a patient's prescription of CholedylR 200 
mg to TheodurR 200 mg will result in an increase in theophylline dose of over 56%. 
This potential for toxicity is not apparent because of the lack of uniformity in 
labelling requirements. Table I indicates the anhydrous theophylline content of 
preparations available in South Africa and enables rational dosing with available 
theophylline preparations. The source of information for construction of the table 
was a combination of personal communications with the relevant pharmaceutical 
companies, reference to manufacturer's package inserts and MIMS Medical 
Specialities (Botha, 1989). It was necessary to liase directly with the pharmaceutical 
manufacturers since the use of theophylline 'salts' with different degrees of 
hydration also results in differences in the content of anhydrous theophylline. Miller 
and Rheeders (1984) for example, consider the theophylline content of Euphyllin 
RetardR to be 281.7 mg. However, the manufacturer, Byk Gulden Pharmaceuticals 
have advised that this actually refers to the monohydrate form of theophylline - the 
anhydrous theophylline content being 256.1 mg. In cases where no information was 
6 
forthcoming from the manufacturer, calculations were based on information 
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Key to notes on Table I 
(1) The theophylline content of liquid dosage forms were variously labelled by 
the manufacturer in terms of a mg per unit dose of liquid e.g. mg per 10 ml 
or mg per Sml. In order to facilitate ease of calculations, all liquid dosage 
forms are reported in Table I as mg per ml. 
(2) Source of information - personal communication with the pharmaceutical 
manufacturer. 
(3) The theophylline content was calculated according to the following 
equation:-
Molecular mass of theophylline 
Theophylline content = 
Molecular mass of theophylline 'salt' 
such that :-
2 * 180.2 









Theophylline content of oxtriphylline = 
283.3 
= 0.636 
All molecular masses were obtained by referring to Martindale, The Extra Pharmacopoeia, 
29th Edition (Reynolds, 1989) 
13 
1.2 CELLULAR BASIS FOR THE MECHANISM 
OF ACTION OF THEOPHYLLINE 
The mechanism by which theophylline exerts its bronchodilator action has not been 
conclusively elucidated. However the literature is replete with proposed 
mechanisms (Boushey and Holtzman, 1987). 
1.2.1 Phosphodiesterase inhibition 
This popular theory for many years suggested that the drug exerted its action by 
inhibition of the enzyme phosphodiesterase. Phosphodiesterase is responsible for 
the hydrolysis of cyclic adenosine monophosphate (cAMP) to 5' adenosine 
monophosphate (5'AMP) - an inactive degradation product. Therefore inhibition of 
this enzyme will result in elevated cAMP levels. In smooth muscle, cAMP acts at 




facilitates the inactivation of myosin light chain kinase. 
inhibits calmodulin-Ca2+ complex formation and thus prevents activation of 
myosin light chain kinase. 
probably facilitates removal of Ca2+ via Ca2+ -ATPase in the cell membrane. 
These effects cause relaxation of smooth muscle (Katzung and Chatterjee, 1987). 




The concentration of theophylline required to inhibit phosphodiesterase in 
vitro would be toxic if used in vivo (Bergstrand, 1980). At therapeutic serum 
concentrations, the degree of phosphodiesterase inhibition is minimal and 
not sufficient to explain the bronchodilation observed (Bukowskyj et al, 1984). 
Other phosphodiesterase inhibitors e.g. dipyridamole and papaverine are not 
bronchodilators (Hendeles et aI, 1985). 
Although theophylline acts synergistically with beta-adrenoceptor agonists in 
increasing cAMP concentrations in tissues and perfused organs its 
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I ----t~~ CONTRACTION 
Actin Actin 
Fig. 2 - Schematic diagram of a smooth muscle cell and some aspects of smooth 
muscle contraction. Calcium ion enters the cell and forms a complex with a small 
protein calmodulin. This complex activates an inactive (i) form of the enzyme 
myosin light chain kinase (MLCK). Activated myosin light chain kinase (MLCK(a», 
in turn, is responsible for the interaction with actin to produce smooth muscle 
contraction (adapted from Katzung and Chatterjee, 1987). 
1.2.2 Antagonism of adenosine receptors 
This theory stems from observations that asthmatics exposed to adenosine 
experience a rapid spasmatic contraction of smooth muscle, perhaps because of 
some idiosyncrasy in the cell receptors for adenosine. Adenosine is a breakdown 
15 
product of cAMP and is formed when cells have little oxygen available to them. It is 
released by animals under hypoxic conditions and in humans with asthma (Murphy, 
1985). 
However, enprofylline (3-propylxanthine) - a xanthine derivative, lacks adenosine 
receptor antagonist properties yet appears to be much more potent than 
theophylline as a bronchodilator (Lunell et ai, 1982). Enprofylline does not have a 
diuretic effect or a stimulant action on the gastrointestinal tract (GIT). In animal 
studies, it has shown substantially less central nervous system (CNS) and cardiac 
toxicity than theophylline. This suggests that antagonism of adenosine receptors may 
relate to the diuretic, cardiac, GIT and eNS effects of theophylline but not 
necessarily to its bronchodilator activity (Hendeles et ai, 1986; Persson, 1986). 
1.2.3 Translocation of calcium 
Calcium plays an essential role in excitation-contraction coupling and it has been 
proposed that theophylline's beneficial effect stems from alterations in cellular 
permeability or intracellular binding of calcium (Stirt and Sullivan, 1981). As 
discussed above (Fig. 2), removal of Ca2+ from the cell by cAMP results in smooth 
muscle relaxation, lending evidence for a role for calcium. 
The main criticism against this theory is that the threshold for these effects to occur 
is much greater than the maximal therapeutic concentration of theophylline in 
serum (Bukowskyj et ai, 1984). 
1.2.4 Stimulation of endogenous catecholamine release 
Stimulation of endogenous catecholamine release may partly explain the mechanism 
of action of theophylline since 50% of the bronchodilator effect can be inhibited by 
the prior administration of propranolol - a beta-adrenoceptor blocking drug. 
Furthermore, plasma and urinary catecholamine levels have been found to be 
increased after the administration of methylxanthines (Church et ai, 1986). Two 
16 
mechanisms for theophylline-induced catecholamine release may be operative here 
- one dependent and the other independent of extracellular calcium (Stirt and 
Sullivan, 1981). 
1.2.5 Other theories 
Several other theories have received little attention to date. These include inhibition 
of the generation of contractile prostaglandins, increased binding of cAMP to 
cAMP-binding proteins (HendeIes et aI, 1985), beta agonist activity and inhibition of 
guanosine monophosphate (GMP) metabolism (Bukowskyj et ai, 1984). 
In summary, there is no one unchallenged theory for theophylline's mechanism of 
action - in fact each of the above may play contributory or complementary roles to 
result in the final observed pharmacodynamic effect. 
17 
1.3 PHARMACOLOGY OF THEOPHYLLINE 
1.3.1 Central nervous system 
Theophylline and the other methylxanthines exert potent stimulant effects on the 
CNS which accounts for both beneficial and adverse effects of these drugs. In low 
and moderate doses, they cause a mild cortical arousal with increased alertness and 
deferral of fatigue (Boushey and Holtzman, 1987). 
The beneficial effects of CNS stimulation relates primarily to theophylline's ability 
to stimulate medullary respiratory centres. Theophylline appears to increase the 
sensitivity of medullary centres to the stimulatory actions of CO2 (Rall, 1985) i.e. it 
increases the hypoxic drive (Lakshminarayan et aI, 1978). This effect finds use in the 
restoration of normal respiratory patterns in patients with Cheynes-Stokes 
respiration; reducing episodes of apnoea in preterm infants and reversing the 
respiratory depression produced by the opioids. 
As the dose is increased, CNS stimulant effects of theophylline produces 
nervousness, insomnia, tremors and hyperesthesia (Rall, 1985). Sleep disorders have 
been documented as reduced sleep quality, decreased total sleep time, decreased 
rapid-eye-movement sleep, and increased frequency of arousal (Bukowskyj et al, 
1984). 
At higher doses, focal and generalised convulsions are produced, man being the 
most sensitive of the several species studied - more sensitive than monkeys, cats, 
guinea pigs, rats and mice (Persson, 1986). 
Theophylline has the ability to constrict cerebral blood vessels. This probably 
accounts for the irreversible brain damage that may be seen as a sequela of 
theophylline toxicity (Persson, 1986). 
18 
1.3.2 Cardiovascular system 
The actions of theophylline on the cardiovascular system are complex and 
sometimes antagonistic. The final result on any particular physiological function, if 
any, depends largely on the conditions prevailing at the time of their administration 
and the dose used. 
Effects on the heart 
The methylxanthines have direct positive chronotropic and inotropic effects on the 
heart (Boushey and Holtzman, 1987). At therapeutic concentrations, a modest 
increase in heart rate is observed. At higher concentrations, a definite tachycardia 
is seen, while some sensitive individuals experience arrhythmias such as premature 
ventricular contractions. 
The drug also reduces left ventricular ejection time index and isovolumetric 
contraction time, consistent with an increase in contractile force and a decrease in 
cardiac preload. In normal individuals inconsistent decreases in cardiac output and 
stroke volume have been observed probably as a result of reflex regulatory changes. 
However, in patients with congestive cardiac failure and clinical cardiac disease, 
where the venous pressure is initially high, an increase in cardiac output has been 
consistently observed. This probably results from a generalised increase in venous 
distensibility and an increase in peripheral vascular capacitance with a resultant 
decrease in cardiac preload (Ogilvie et al, 1977). 
Blood vessels 
Theophylline causes a decrease in peripheral vascular resistance. This effect, 
together with the increased cardiac output, results in a transient increase in 
peripheral blood flow. The overall effect on arterial blood pressure, however, is 
minimal due to possible variable effects on different vascular beds and to 
compensatory mechanisms (Ogilvie et al, 1977). 
Contrary to their effect on peripheral vascular resistance, theophylline causes an 
increase in cerebrovascular resistance leading to a decrease in cerebral blood flow 
and the oxygen tension in the brain (Rail, 1985; Persson, 1986). 
19 
Under certain circumstances theophylline increases coronary blood flow. It is 
uncertain whether this would be of benefit in coronary insufficiency as the drug also 
increases the work of the heart (Rail, 1985). 
1.3.3 Urogenital system 
Theophylline causes an increase in the production of urine, an effect which appears 
to be due to a combination of an increase in glomerular filtration rate and a 
decrease in renal tubular sodium ion reabsorption (Boushey and Holtzman, 1987). 
Tolerance usually develops to this diuretic effect but it may be important in an 
already dehydrated patient (Persson, 1986). 
The drug is also reported to inhibit uterine contractions (Hendeles & Weinberger, 
1983). 
1.3.4 Gastrointestinal system 
Theophylline significantly increases both acidity and volume of gastric secretion by 
increasing the secretion of both acid and pepsin (Rail, 1985; Persson, 1986). In 
addition, the drug causes relaxation of the lower oesophageal sphincter, an effect 
that may contribute to gastroesophageal reflux (Persson, 1986). 
1.3.5 Respiratory system 
The most important pharmacological action of theophylline is its ability to relax 
bronchial smooth muscle throughout the bronchial tree. The bronchodilator effect is 
seen irrespective of the stimulus for bronchoconstriction i.e. theophylline is a 
functional antagonist of bronchoconstrictor mediators (Persson, 1986). 
Theophylline has recently been shown to have a potent effect on diaphragmatic 
contractility in normal persons - it improves contractility before and after induction 
of diaphragmatic fatigue. This apparent ability to reduce diaphragmatic fatigability 
and to improve contractility may account for the clinical improvement often seen in 
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patients with non-reversible obstruction after theophylline therapy (Jenne, 1984; 
Bukowskyj et at, 1984). It also assumes importance when respiratory failure 
threatens. 
It has been shown clinically that theophylline increases mucociliary transport 
immediately and during prolonged treatment. In vitro studies have shown that the 
xanthines are potent stimulants of ciliary beat frequency (Persson, 1986). 
Preliminary animal studies suggest that xanthines may attenuate microvascular 
leakage and increase release of alveolar surfactant material (Persson, 1986). 
1.3.6 Metabolic actions 
Theophylline may increase the release of noradrenaline, adrenaline, dopamine, 
renin, gastrin, insulin, glucagon, glucose, cortisol, parathyroid hormone, growth 
hormone and free fatty acids. Most of these effects may not occur to any significant 
degree at therapeutic serum levels (Persson, 1986). 
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1.4 TOXICITY 
Side-effects from theophylline may be transient, minor or major. These are usually 
dose and serum concentration dependent. 
1.4.1 Transient - 10 to 20 v.g/ml 
Within the therapeutic range, side effects are mild, caffeine-like effects to which 
patients rapidly acquire tolerance. These are often associated with attempts to 
rapidly achieve therapeutic serum concentrations in ambulatory patients with 
chronic asthma. 
The effects seen are nausea, cramps, insomnia and headache. Small initial doses and 
slow titration over about 7 - 10 days helps to reduce the incidence of these effects 
(Hendeles et aI, 1986). 
1.4.2 Minor - 15 to 35 v.g/ml especially> 20 v.g/ml. 
More severe and persistent adverse effects are associated with serum concentrations 
above 20 v.g/ml. 
These include persistent nausea, vomiting, insomnia, nervousness, irritability, 
headache, diarrhoea and sinus tachycardia. 
In premature newborns, tachycardia frequently occurs at concentrations above 10 
v.g/ml while most other patients experience these effects at concentrations greater 
than 30 v.g/ml (Hendeles et aI, 1986). 
1.4.3 Major - > 35 v.g/ml especially> 40 v.g/ml 
The effects seen here include confusion, agitation, hypotension, hyperglycaemia, 
ventricular arrhythmias, seizures, brain damage and death. 
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Among infants and small children, severe toxicity has most often been the result of 
inadvertent administration of multiple adult doses of suppositories. Cocoa butter 
based suppositories have been associated with delayed and erratic absorption and 
are therefore currently not recommended (Hendeles et ai, 1986). 
In adults, serious theophylline intoxication frequently has been reported in patients 
with cardiac decompensation or hepatic dysfunction where clearance of the drug 
was impaired and excessive serum concentrations accumulated (Jacobs and 
Senior, 1974). 
While theophylline-induced ventricular arrhythmias usually respond promptly to 
lignocaine, theophylline-induced seizures are generally unresponsive to 
anti-convulsants (Hendeles et ai, 1986). 
An important point to note is that from observations on patients who experienced 
seizures (Zwillich et ai, 1975), minor adverse effects do not always precede the more 
life-threatening side-effects and that these minor effects (nausea and vomiting) 
cannot be relied upon as a dosing end-point - only serum theophylline concentration 
measurements can reliably forewarn of impending life-threatening toxicity (Hendeles 
et ai, 1986). 
1.4.4 Other 
Other adverse reactions to theophylline include the rare occurrence of dehydration 
especially in children - due to a combination of a loss of fluids as a result of 
vomiting, decreased fluid intake, and the transient diuretic action of the drug 
(Hendeles and Weinberger, 1983). 
Patients with ulcer disease may experience an increase in symptoms due to 
theophylline's ability to increase gastric acid secretion (Persson, 1986; Hendeles and 
Weinberger, 1983). 
Allergic reactions (urticaria, exfoliative dermatitis) reported with theophylline use 
have been associated with the use of aminophylline (theophylline ethylenediamine). 
It has been suggested that this may be a hypersensitivity reaction to the 
ethylenediamine component (Elias and Levinson, 1981). 
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1.5 PHARMACOKINETICS OF THEOPHYLLINE 
1.5.1 Absorption 
Absorption of theophylline from liquids and plain un-coated tablets (i.e. when 
disintegration and dissolution is not delayed), is rapid, consistent and complete 
(Hendeles et ai, 1977; Upton et ai, 1980). 
The absorption efficiency of aqueous and alcoholic liquid formulations of 
theophylline is similar (Koysooko et ai, 1975) and there is therefore no reason to use 
alcohol as a vehicle since it is more likely to cause side effects than contribute to 
efficacy. 
The use of microcrystalline theophylline in various tablet and capsule formulations 
does not enhance absorption to any significant degree (Sansom et ai, 1979). 
In the past, enteric coated theophylline preparations were developed with the 
intention of avoiding the side-effect of nausea and vomiting. Studies have 
demonstrated that this side-effect is not due solely to a local irritant action and 
therefore, this rationale is not valid and may in fact be disadvantageous. Enteric 
coating of theophylline tablets has been shown to decrease dissolution and can 
result in incomplete or unpredictable delays in absorption (Upton et ai, 1980a). 
The administration of theophylline with food has been found to affect the rate but 
not the extent of theophylline absorption in rapidly absorbed formulations. This 
effect is not considered to be clinically important in chronic dosing (Hendeles et ai, 
1986). However, the influence of food on the absorption of theophylline becomes 
important when dealing with certain slow release products. Formulation dependent 
interactions between slow release preparations and food composition, temperature, 
quantity and/or density and time of food intake in relation to concomitant drug 
intake have been described (Schulz et ai, 1987). These interactions have resulted 
either in delays in effect, or in contrast, and more importantly, in toxicities due to 
dose dumping. It is clear therefore, that in the choice of a sustained release product 
for routine clinical use, only a preparation whose release is unaffected by food and 
factors such as pH should be considered. 
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Concurrent administration of antacids contammg aluminium and magnesium 
hydroxide decreases the rate but not the extent of absorption of theophylline from 
plain, un-coated tablets. This may be due to a combination of physical adsorption as 
well as to increased ionisation of theophylline at the higher pH. This effect is 
probably unimportant when considering chronic theophylline therapy (Shargel et ai, 
1981). 
A circadian pattern in theophylline absorption has been reported with slower 
absorption occurring at night. This results in higher morning trough levels for most 
of the slowly absorbed products. This may find clinical relevance in timing of blood 
samples in that this should be standardised within patients (Taylor et ai, 1983; 
Glynn-Bamhart et ai, 1988) . 
The only parenteral route of administration that is currently recommended is the 
intravenous route. Since the maximum solubility of theophylline in water is ± 8 
mg/rnl at physiological pH and temperature, intramuscular injection of available 
parenteral preparations results in precipitation at the injection site, pain, irritation 
and slow absorption (Hendeles et at, 1986). 
Rectal suppositories made with a cocoa butter base are not recommended since 
they have been repeatedly associated with slow and erratic absorption (Hendeles et 
al,1986). 
In children, the use of suppositories have frequently been associated with severe 
theophylline toxicity, most often due to the administration of multiple adult doses 
(Hendeles et ai, 1986) probably because of the delayed and erratic absorption. The 
rate and extent of absorption from rectal solutions (and experimental polyethylene 
glycol suppositories) is similar to that of oral solutions and may be used if the 
patient is unable to take oral medications (Hendeles et ai, 1986). 
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1.5.2 Distribution 
After theophylline enters the systemic circulation, between 40 - 60% becomes 
bound to plasma proteins. Evidence seems to favour the lower percentage of 40% 
since the value of 60% may have been obtained because of the lower temperature 
and increased pH conditions that occurred during in-vitro testing (Shaw et aI, 1982; 
Hendeles et aI, 1986). 
Protein binding is decreased in premature newborns, in adults with hepatic cirrhosis 
or un-corrected acidemia and in the elderly (Hendetes et at, 1986). Preliminary 
results indicate that plasma protein binding is also markedly reduced in pregnancy, 
averaging 11.1 ± 4.7% in the second trimester; 13.0 ± 5.9% in the third trimester 
and 28.1 ± 2.8% in the remote postpartum period (Frederiksen et at, 1986). As a 
result of this decreased protein binding, the apparent volume of distribution (Vd) is 
slightly larger in these patients (Hendeles et at, 1986). In obesity, however, the 
opposite situation prevails and Vd is found to be decreased (Bukowskyj et aI, 1984). 
Apart from these conditions, Vd remains relatively unchanged even when clearance 
is altered. It ranges from 0.3 - 0.7 L/kg with an average of about 0.45 L/kg among 
both adults and children (Loughnan et at, 1976; Hendeles et aI, 1978; Hendeles et 
at, 1986). 
After intravenous injection, theophylline serum concentrations equilibrate with 
tissue concentrations within 1 hour. The drug passes readily across the placenta 
(Labovitz and Spector, 1982), blood-brain barrier (Hendeles et aI, 1986) and into 
breast milk. A milk to serum ratio of 0.7 has been reported (Yurchak and Jusko, 
1976). 
1.5.3 Metabolism and excretion 
Theophylline is eliminated primarily by biotransformation (Fig. 3) in the liver with 
only about 10% of an administered dose being recovered in the urine unchanged 
(Rall, 1985). Therefore dosage adjustments are not usually necessary in patients with 
renal function impairment. 
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Fig. 3 - Diagram illustrating the hepatic biotransformation of theophylline and 
urinary excretion of metabolites (Hendeles et al, 1986). 
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Biotransformation is mediated by the liver microsomal mixed - function oxidase 
system, most likely the cytochrome P-450 system which is responsible for the 
hydroxylation and N-demethylation of theophylline over multiple parallel pathways 
by both first order and capacity limited processes (Hendeles et ai, 1986). 
The major metabolite is 1,3-dimethyluric acid accounting for approximately 40 -
50% of excreted metabolites. Lesser metabolites are theophylline, 3-methyIxanthine 
and 1-methyluric acid which each accounts for 10 - 15% and 1-methyIxanthine 
which is excreted in smaller amounts. Xanthine oxidase has been identified as the 
enzyme responsible for subsequent biotransformation of 1-methyIxanthine to 
1-methyluric acid. About 6% of a dose of theophylline is N -met h y I ate d to 
caffeine which in turn is converted to paraxanthine (Bukowskyj et ai, 1984; Hendeles 
et ai, 1986). 
In the premature neonate, about 50% of the dose is excreted in the urine unchanged 
(hence dosage adjustment is necessary in renal failure) and the remainder 
undergoes N-methylation to caffeine and C-8 hydroxylation to 1,3-dimethyluric acid. 
Caffeine has a longer half-life in neonates and may result in accumulation. Caffeine 
may also be responsible for beneficial effects seen when theophylline is 
administered to neonates with apnoea (Aranda et ai, 1977). 
Theophylline metabolism exhibits a somewhat unique situation in that overall 
clearance is linear but each metabolic pathway is in fact non-linear. This is the result 
of different Km and Vmax values for the different metabolites with the major 
metabolite 1,3-dimethyluric acid having the highest values (Tang-Liu et ai, 1982). 
However linearity in theophylline kinetics depends on the serum theophylline 
concentration and the overall Km value for the individual patient. An estimated 
mean pooled Vmax of 1960 mg/day and mean Km of 24.1 mg/l has been reported 
in the literature (Wagner, 1985). 
Clinically, this can be important, in that, at the higher dosage range a small increase 
in dose can result in disproportionately large increases in serum concentration. Such 
experiences have in fact been reported in both children and adults (Hendeles et 
al,1986). 
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1.5.3.1 Factors affecting theophylline clearance 
It has been widely reported that there is a large interindividual variation in the rate 
of theophylline biotransformation (lenne et aI, 1972; lusko et aI, 1979). This is due to 
the fact that theophylline is primarily eliminated via the hepatic route and numerous 
factors are known to affect the functional capability of the liver. These are discussed 
below. Table 11 should be referred to for actual clearance values as reported in the 
literature. 
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Table 11 - Summary of theophylline clearance 
values for various patient populations 
Population characteristics 
Premature neonates with apnoea 
Term infants : under 6 months 
: 6 to 11 months 
Young children : 1 - 4 years 
Older children : 4 - 12 years 
: 13 - 15 years 
: 16 - 17 years 
Adults: otherwise healthy 
non-smoking asthmatics 
Healthy non-smoking volunleers 
Elderly - non -smokers with normal 
cardiac, liver and renal function 
CONCURRENT ILLNESS 
Cor pulmonale 
Cystic f ibrosis 
Acute pulmonary oedema 
Liver disease - cirrhos is 




Marijuanha a. cigarettes 
Cigarettes (heavy smokers) 
Ex- cigarette smokers - for at least 2 years 
Elderly smokers 
PREGNANCY_ 
24 - 26 weeks pregnant 
36 - 38 weeks pregnant 
6 - 8 weeks postpartum 
more than 6 months postparlum 
adapted from Hende/es et 8/, 1986 
• Frederiksen e/ 8/, 1986 
Age, mean (SD) 
(years) 
7.5 (4.4) days 
41 (12) days 
18 (2) weeks 






20 - 32 (25.5) 
67 (5.7) 
5 - 15 
64 






20 - 25 
19 - 27 
22 - 31 (27) 
22 - 39 (28) 















































0.07 5 (0.028) 
0.020 (0.004 - 0. 141) 
0026 (0.008 - 0.198) 









Theophylline clearance is reduced in infants and elderly patients. Children up to 
adolescence have rapid theophylline clearance while non-smoking adults have 
values between these two extremes. In infants the decreased clearance rate is 
related to oxidative pathways that have not yet been established. Hence the urinary 
excretion consists largely of unchanged theophylline or caffeine. At age 
approximately 1 year, clearance increases and is approximately 40% greater than 
that of adults. This increased value is maintained throughout childhood and into 
adolescence. Thereafter the clearance progressively decreases with age. This may be 
related to either relative loss of functional ability or to the amount of enzymes 
available (Bukowskyj et aI, 1984). The increased incidence of congestive heart failure 
and liver function impairment in the elderly may also be a contributory factor (Jusko 
et aI, 1979). 
1.5.3.1.2 Gender 
Available evidence suggests that there is no clinically significant difference between 
males and females in their rates of theophylline clearance (Jusko et aI, 1979; 
Hendeles et aI, 1981). 
1.5.3.1.3 Concurrent illness 
Fever 
Clearance of theophylline is reduced during febrile viral respiratory tract infections. 
It is not clear whether this is due to the fever or the viral infection since chemically 
induced fever caused a decrease in clearance while afebrile volunteers who had 
been administered influenza vaccine also showed a decrease in clearance (Hendeles 
et aI, 1983). Whatever the cause, the magnitude of the decrease in clearance is such 
that a decrease in dose may be necessary in order to avoid toxicity (Hendeles et aI, 
1985) especially if maintenance serum theophylline concentrations lie at the upper 
end of the therapeutic range. 
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Heart disease 
Several authors describe a decrease in theophylline clearance in patients with 
congestive heart failure, either left or right sided (Bukowskyj et aI, 1984; Hendeles et 
aI, 1986). A large number of the reported cases of serious theophylline toxicity have 
occurred in patients with congestive heart failure who have been prescribed 
standard doses. 
Possible mechanisms for the decrease in clearance are: 
* passive congestion of the liver which results in hepatocellular damage. This 
may alter the capacity of the liver to extract and metabolise theophylline. 
* 
* 
decreased liver blood flow . However the low extraction ratio tends to make 
this explanation less likely. 
liver hypoxia secondary to inadequate perfusion. 
Patients with congestive heart failure may frequently need theophylline therapy 
(due to the drug's positive inotropic action, diuretic action and for symptomatic 
treatment of the wheezing symptoms). Therefore, in order to avoid toxicity, dosage 
should be very carefully titrated using serum theophylline concentration 
measurements. 
Resolution of the congestive heart failure has resulted in marked improvement 
(increase) in theophylline clearance (Bukowskyj et aI, 1984). 
Liver disease 
Liver disease results in a decrease in theophylline clearance due to liver cell injury. 
This decrease may be large and is of major clinical importance. Some authors have 
found a change in the pattern of urinary excretion of theophylline metabolites. The 
degree of decrease in theophylline clearance depends on the type of liver 
dysfunction, the most marked decrease occurring in decompensated cirrhosis, while 
patients with cholestasis had clearance values similar to that of normals (Bukowskyj 
et ai, 1984). 
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Cystic fibrosis 
Adolescents with cystic fibrosis have been found to have a more rapid than average 
rate of clearance (Isles et aI, 1983). 
Hyperthyroidism 
Hyperthyroidism causes an increase In theophylline clearance possibly due to 
increased activity of hepatic enzymes and increased hepatic blood flow. The 
observation that there is a correlation between thyroxine and theophylline clearance 
suggests that interindividual differences in thyroid function may contribute to 
variability in theophylline clearance (Hendeles et aI, 1985). 
1.5.3.1.4 Diet 
A high protein, low carbohydrate diet increases the rate of theophylline clearance, 
while a low protein, high carbohydrate diet decreases theophylline clearance 
compared to a normal diet. Ingestion of charcoal broiled beef can also increase 
theophylline clearance due to the influence of enzyme inducing hydrocarbons from 
the charcoal. 
However, these effects are unlikely to be of any real clinical significance unless 
permanent drastic changes in diet are made (Hendeles et aI, 1986). 
1.5.3.1.5 Smoking 
Cigarette and marijuanha smokers have rapid clearance and these patients usually 
require much higher doses on average in order to achieve serum theophylline 
concentrations within the therapeutic range. The reason for this effect is the 
presence of enzyme inducing substances in cigarette smoke e.g. polycyclic 
hydrocarbons (Hunt et aI, 1976). The effect of cigarette smoking in causing an 
increase in clearance may modify the effect of other factors that tend to decrease 
theophylline clearance e.g. old age. These patients therefore tend to have slightly 
higher clearance than their non-smoking counterparts. 
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Upon cessation of smoking theophylline clearance will return to normal very slowly 
(Hunt et at, 1976) with some reports indicating a timespan of up to 2 years. 
1.5.3.1.6 Pregnancy 
Patients in their second and third trimesters of pregnancy appear to have a 
decreased hepatic clearance of theophylline. Frederiksen et al (1986) have shown 
that plasma protein binding is decreased during pregnancy hence increasing free 
theophylline concentrations. This tends to expose the mother and the foetus to 
increased theophylline concentrations and potential toxicity. Carter et al (1986) 
reports 2 patients who experienced signs of theophylline toxicity and who required 
dose reductions during pregnancy. The question of the influence of the state of 
pregnancy on theophylline clearance appears important and warrants further 
investigations. 
1.5.3.1.7 Drug interactions 
Erythromycin 
Erythromycin has been reported to cause a decrease in theophylline clearance. The 
mechanism of the interaction involves inhibition of the cytochrome P-450 mixed 
function oxidase system. The effect was found to be dependent on dose and duration 
of therapy. Theophylline may also cause a decrease in erythromycin levels so that 
the physician is faced with a dual problem - potential theophylline toxicity and 
inadequate erythromycin concentrations. Similar results have been observed with 
other macrolide antibiotics e.g. troleandomycin (Prince et aI, 1981; LaForce et aI, 
1981). 
Other antibiotics 
Other antibiotics such as amoxycillin, ampicillin, cefaclor, metronidazole and 
tetracycline have no effect on theophylline clearance (Bukowskyj et aI, 1984; 
Hendeles et ai, 1986). Although initial animal studies showed no interaction between 
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rifampicin and theophylline (Bukowskyj et aI, 1984), increases in clearance of up to 
79% after 14 days of concurrent administration, probably due to induction of the 
cytochrome P-450 system, have been reported in humans. The resultant decrease in 
serum theophylline concentrations may imply loss of asthma control. It is 
recommended, therefore, that serum theophylline concentrations be measured 5 
days after commencement of rifampicin therapy with a view to dose adjustment if 
necessary (Hauser et aI, 1983). 
Enoxacin, a relatively new antibiotic, has been associated with higher than expected 
serum theophylline concentrations and symptoms of toxicity in 8 of 10 patients 
(Wijnands et aI, 1984). In one patient the steady state serum theophylline 
concentration doubled following concurrent administration of intravenous 
aminophylline and oral enoxacin for 3 days. 
Cimetidine and ranitidine 
Cimetidine, a histamine H2 receptor antagonist has been reported to cause a 
decrease in theophylline clearance. This effect occurs rapidly with changes seen 
within 24 hours of the first dose. The mechanism appears to be competitive 
inhibition of the hepatic microsomal mixed-function oxidase system. This interaction 
is considered to be life-threatening with at least 1 report of a fatality. It has not 
been noted with the structurally dissimilar H2 receptor antagonist ranitidine 
(Bukowskyj et aI, 1984; Hendeles et aI, 1986), although more recent reports suggest 
the contrary (Muir et aI, 1989; Roy, 1989). 
Antiepileptic drugs 
The antiepileptic drugs phenobarbitone, carbamazepine and phenytoin have been 
reported to cause increases in theophylline clearance, the degree of increased 
clearance ranging from a mean of 25% for phenobarbitone, 59% for carbamazepine 
and 75% for phenytoin (Hendeles et aI, 1986). In the case of phenytoin a mutual 
decrease in theophylline and phenytoin levels may occur. In order to avoid loss of 
asthma or seizure control, these patient's therapy should be adjusted on the basis of 




A decrease of 21 % in theophylline clearance occurred in patients given high doses 
(600 mg/daily) of allopurinol (Hendeles et aI, 1986). At lower doses of 300 mg/daily, 
Vozeh et a~ 1980 did not notice any alteration in the theophylline clearance. 
The mechanism of the interaction is unlikely to be due to inhibition of xanthine 
oxidase, since this enzyme is not involved in hydroxylation or demethylation of 
theophylline. It appears as though allopurinol is a non-specific inhibitor of hepatic 
microsomal enzyme activity (Hendeles et a~ 1986). 
Oral contraceptives 
A decrease in theophylline clearance of approximately 34% was observed when 
compared to a group of age-matched controls in 8 non-smoking women who had 
been taking oral contraceptives for 6 months or longer (Bukowskyj et aI, 1984). The 
mechanism is presumably one of competitive inhibition of hepatic microsomal 
enzyme activity. 
Theophylline toxicity may be avoided in these patients if doses are adjusted on the 
basis of serum concentration measurements (Hendeles et at, 1986). 
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The principles of applied pharmacokinetics with particular emphasis on 
theophylline 
2.1 INTRODUCTION 
Therapeutic drug monitoring is an expanding new scientific discipline that can make 
important contributions to treatment in coronary care, intensive care , general 
medicine and surgery, and general practice. It involves the use of drug 
concentrations, pharmacokinetic principles and pharmacodynamic criteria to 
optimise drug therapy in individual patients. 
With some drugs optimisation is accomplished primarily by minimising the 
probability of toxicity, while with other drugs benefits are achieved by increasing the 
probability of the desired therapeutic effects. With the drugs for which therapeutic 
drug monitoring is indicated, a balance between these two end-points is sought. 
2.1.1 Which drugs should be monitored? 
Drugs which have a wide therapeutic ratio i.e. they do not produce toxicity at doses 
required for clinical effect, will not usually require monitoring. For such drugs e.g. 
penicillin, it is common to use dosages that are high enough to ensure "therapeutic 
concentrations" in essentially all patients, since toxicity is of little concern. An 
exception to this practice might arise when non-compliance or malabsorption is 
suspected, or when the cost of the drug is so great that therapy with the minimum 
effective dose is advantageous (Evans, 1986) . 
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2.1.2 Why monitor theophylline levels? 
In many discussions on the value of therapeutic drug monitoring in clinical 
medicine, the successes achieved with measurement of serum theophylline 
concentrations have been used as the descriptive model. The pre-eminence of 
theophylline in this context is based upon the following: 
* The relationship between dose and response is erratic and unpredictable. 
This is secondary to a poor dose-serum concentration relationship. 






Theophylline has a low toxic to therapeutic ratio. 
There is a large interindividual variability in rate of theophylline elimination. 
Serum concentrations may be affected by many factors that affect liver 
microsomal enzyme function and alter elimination kinetics. 
Theophylline IS administered to the chronic asthmatic as a prophylactic 
agent. 
(Finn et al, 1981; Hendeles and Matthay, 1986) 
2.2 ANALYTICAL METHODS 
During the past 25 years enormous advances have been made in the development of 
sensitive and specific methods for the determination of drug and drug metabolite 
concentrations in biologic fluids. The improved methodologies have resulted in an 
almost explosive proliferation of commercial drug assay kits and instrumentation. 
This is particularly true in the case of theophylline. The different methods available 
differ in important aspects including sensitivity, specificity, sample size needed, 
technical difficulty, amount of technician time required and initial equipment costs 
(Hendeles and Weinberger, 1981). The following discussion traces the evolution of 
the available theophylline assay techniques from initial tedious, technically difficult 
assays to modern day automated immunoassays with extremely rapid turnaround 
time. 
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2.2.1 UV spectrophotometric assay 
In this method theophylline is extracted from serum with organic solvent and the 
absorbance of ultraviolet light is measured in a spectrophotometer. 
Since most laboratories have a spectrophotometer, the method does not require an 
investment in new equipment. However, it does require a relatively large sample 
size. In addition, a variety of commonly used drugs (e.g. furosemide and aspirin) 
interfere with this assay, producing false results. Other disadvantages include the 
need for more technician time and the poor reproducibility of the results compared 
to other available methods. For these reasons, the UV spectrophotometric assay 
method should not be relied upon to guide dosage adjustment in the clinical setting 
(Hendeles and Weinberger, 1981). 
2.2.2 Gas-liquid chromatography 
The poor specificity and relatively large sample SIze required for the UV 
spectrophotometric method lead investigators to develop gas-liquid chromatography 
(GLC) methods for measuring theophylline (Hendeles and Weinberger, 1981). 
The first step in a GLC assay involves an extraction step to dissolve the drug into an 
organic solvent. The sample plus an internal standard with chemical properties 
similar to the drug being assayed, is then injected into the gas chromatograph. This 
is carried into a high temperature column by an inert gas (e.g. helium) which 
constitutes the mobile phase. Column temperatures of lOOoC to 350°C volatilise the 
sample, which then comes into contact with an inert stationary phase, usually coated 
with a nonvolatile liquid. As the mobile phase passes through the column, the 
analyte is separated from other sample constituents based on affinity for the 
stationary phase. The mobile phase then passes from the column to a detecting 
device that draws curves whose peaks correspond to the concentrations of the 
unknown substances. The internal standard produces a reference peak. Detecting 
devices include electron capture, mass spectrometry, or more commonly, flame 
ionisation (BottoifJ and Stewart, 1986). 
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Advantages of GLC include flexibility in drug assays (by altering column length and 
temperature), simultaneous assay of parent drug and metabolites and the ability to 
use small sample volumes. The disadvantages are the time consuming procedure, 
high equipment cost, column deterioration and the need for a skilled analyst. Few 
laboratories currently use this technique (HendeZes and Weinberger, 1981; BottorfJ 
and Stewarl, 1986). 
2.2.3 High pressure liquid chromatography (HPLC) 
Liquid chromatography (LC) is similar to GLC except that the mobile phase is a 
liquid, usually a mixture of acetonitrile or methanol with water. Compared to GLe, 
the need for high temperatures is eliminated and columns packed with stationary 
phase are kept at ambient temperature. Substances are separated in LC according 
to their solubility in aqueous or organic solvents. Highly polar compounds will be 
more soluble in highly polar solvents like water, whereas, less polar drugs will 
dissolve better in organic solvents such as chloroform. As the mobile liquid phase 
and the stationary phase come in contact in a column, separation occurs in a fashion 
similar to other chromatographic methods. 
The addition of 200 to 1000 pounds of pressure per square inch to the separation 
column converts liquid chromatography to high pressure liquid chromatography 
(HPLC), producing rapid separation and determination of drug concentrations. 
Reverse phase liquid chromatography uses a non-polar column packing and polar 
mobile phase. This technique allows for the direct determination of theophylline 
concentrations within 10 - 20 minutes without the need for an organic solvent 
extraction step (BottorfJ and Stewart, 1986). 
Advantages of this method include the low cost, once the method has been 
established; the ability to operate without the need for commercially available 
reagent kits and the ability to simultaneously measure caffeine which is a clinically 
important metabolite in neonates. 
The disadvantages are the high initial cost of the equipment; the high degree of 
technician skill required and the difficulty in performing stat or small batch testing 
due to the equipment preparation time required. Large doses of some drugs e.g. 
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ampicillin, cephalothin, acetazolamide and trisulfapyrimidine cause falsely elevated 
results under some operating conditions and represents another disadvantage of this 
technique (Hendeles and Weinberger, 1981; Bottorff and Stewart, 1986). 
2.2.4 Enzyme immunoassay 
In the enzyme multiplied immunoassay technique (EMITR), a known quantity of 
analyte labelled with an enzyme (glucose-6-phosphate dehydrogenase) competes 
with the drug from the patient sample for antibody binding sites. At equilibrium, the 
amount of unbound enzyme-labelled analyte will be directly proportional to the 
concentration of drug. Substrate (nicotinamide adenine dinucleotide - NAD) added 
to the sample catalyses an enzymatic indicator reaction (NAD to NADH) that can 
be detected spectrophotometrically. Since the antibody-bound enzyme is inactivated 
or reacts more slowly with substrate, the unbound or free portion is responsible for 
the detection reaction. Therefore, the fractions need not be separated prior to 
substrate addition and the assay is termed homogeneous. 
The advantages of this method include the rapid turnaround time and high 
precision. The disadvantages are the need to frequently re calibrate the instrument 
and the technician time required to perform dilution steps to analyse abnormally 
high serum concentrations (Bottorff and Stewart, 1986). 
This technique is one of the more popular methods currently available. 
2.2.5 Radioimmunoassay 
The labelling molecule for radioimmunoassay (RIA) can be either 57Co, 3H or more 
commonly, 1251 At equilibrium, the amount of radioactive labelled analyte bound to 
antibody is inversely related to the amount of analyte from the patient sample. 
Before measuring drug concentration, the sample must first be separated into its 
free and bound phases to prevent radiation interference. Radioimmunoassay 
procedures are therefore regarded as being heterogeneous. Once separated, drug 
levels are determined by gamma counting equipment (Bottorff and Stewart, 1986). 
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The advantages are high sensitivity, ability to detect concentrations in the picogram 
range and small sample size requirements. The disadvantages are the long 
turnaround times; the many interfering substances; radiation hazards; inconvenience 
of recording and disposing radioactive waste; short shelf life of RIA reagents and 
the need for daily calibration of the instrument. This method is now less popular 
because of these many disadvantages (Hendeles and Weinberger, 1981; Bottorff and 
Stewart, 1986). 
2.2.6 Fluorescence polarisation immunoassay 
This is a variation of the enzyme immunoassay technique in which the antigen label 
is fluorescein. Fluorescein-tagged drug and unlabelled drug are incubated with 
antibody and then excited with light passed through a polarising lens. With high 
drug concentrations, there is an increase in unbound fluorescent-labelled molecules 
that tumble free in solution causing the light to be depolarised upon emission. At 
low drug concentrations, the labelled antigen-antibody complex rotates more slowly 
and polarisation of the emitted light is maintained (Bottorff and Stewart, 1986). 
The advantages are the high degree of automation; rapid turnaround times, good 
sensitivity (lower limit of detection is 0.5 }J.g/ml at the 95% confidence interval), 
good stability of reagents; good stability of calibration curves and the ability to 
analyse small or large batches of samples. A disadvantage is the presence of 
background interference inherent in some serum samples. In order to minimise 
this, blank readings are taken and background interferences are subtracted. (Bottorff 
and Stewart, 1986; Hendeles et a11986) 
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2.2.7 Newer techniques 
2.2.7.1 Ames Diagnostics have recently introduced a new immunoassay technique 
that utilises a dry reagent contained on a plastic strip - see Chapter Four for 
an evaluation of this technique. 
2.2.7.2 Syntex Medical Diagnostics recently developed a method to analyse 
theophylline concentration without the need for a processing instrument. 
This system combines the technology of immunoassay with thin layer 
chromatography. The specificity of the assay should be comparable to that of 
other immunoassays since the principle involved viz. use of monoc1onal 
antibodies is the same. It requires only 12 } .. Ll of whole blood from finger stick 
and turnaround time is about 15 minutes (Hendeles et ai, 1986). The ability to 
use whole blood rather than serum or plasma means that the time-consuming 
centrifugation step is eliminated. This is a real advantage, since in many 
assay techniques currently available, centrifugation of the sample is the rate 
limiting step. 
2.3 SALIVA THEOPHYLLINE CONCENTRATIONS 
In order to avoid the trauma of venipuncture in children, it has been suggested that 
theophylline concentrations in saliva be used to estimate indirectly the serum 
concentration. However, numerous studies have demonstrated that the saliva to 
serum concentration ratio often does not remain stable in the same patient. In view 
of the danger involved in possible dosage adjustment errors and the ability of newer 
techniques to measure levels using as little as 50 ~l of serum (Le. sufficient from a 
finger or a heel stick), saliva measurements are not recommended at this time 
(Hendeles et ai, 1986). 
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2.4 WHEN TO DRAW SAMPLES 
Since drug administration is a dynamic process, the timing of sample collection is 
critical to its proper interpretation. It is important that samples for serum 
theophylline concentration monitoring be drawn at steady state since levels 
measured before steady state may be erroneously low. Steady state conditions 
usually occurs after approximately 48 hours of stable dosage. However if computer 
facilities are available to perform the relevant complex calculations, then samples 
may be drawn prior to steady state. Blood samples should not be drawn during the 
absorption phase in view of the many factors that affect absorption of theophylline; 
neither should levels be drawn during the distribution phase since therapeutic effect 
correlates with levels obtained after completion of the distribution phase (Robinson 
and Taylor, 1986). 
The following recommendations serve as a guide to the determination of 
appropriate sample collection times. 
Intravenous therapy (Taylor and Finn, 1981) 
Loading dose - Thirty minutes after administration. 
Infusions - Prior to commencing the infusion (if the patient has a history of 
theophylline use in the previous 24 hours) and 4 - 8 hours later. Thereafter, samples 
are drawn as needed to ensure that the desired concentration is maintained. 
Oral therapy (Taylor and Finn, 1981) 
Peak level - Solution or solid dosage form with rapid release characteristics: 2 hours 
after the dose. 
Slow release formulations: 4 hours after the dose. 
Trough levels - immediately before the next oral dose. 
The above recommendations serve as a guide and should not be viewed as absolute. 
Factors such as reason for assaying the sample e.g. the assessment of possible drug 
toxicity necessitates that sample collection times be individualised. 
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2.5 STABILITY OF SERUM THEOPHYLLINE CONCENTRATIONS 
Whole blood samples containing theophylline may be stored for up to 3 days either 
at room temperature (25°C) or under refrigeration (4°C). Serum samples containing 
theophylline may be stored for up to 3 days at 25°C; 7 days at 4°C and 48 weeks 
when frozen at -20°C (Johnson et ai, 1984). 
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2.6 THEOPHYLLINE DOSING METHODS AND INTERPRETATION OF 
SERUM CONCENTRATIONS 
The interpretation of serum theophylline concentrations requires an understanding 
of the basic concepts of pharmacokinetics and a background in pathophysiology and 
pharmacotherapeutics (Beane, 1979). Numerous dosing methods have been 
developed in an attempt to improve the relationship between dose, serum 










2.6.1 Standard doses 
In 1973, Mitenko and Ogilvie recommended an aminophylline loading dose of 
5.6 mg/kg and a continuous infusion rate of 0,9 mg/kg/hr to achieve target serum 
concentrations of 10 - 20 }.lg/mI. 
While these recommendations appeared to be appropriate at the time, numerous 
investigators (Weinberger et aI, 1976; Kordash et aI, 1977; Hendeles et aI, 1977) 
subsequently evaluated these guidelines and found that administration of this 
standard dose frequently gave rise to serum theophylline concentrations greater 
than 20 }.lg/ mI. 
This led to the suggestion that "it is not possible to achieve optimal therapeutic 
aminophylline dosage without monitoring serum theophylline concentrations." 
(Weinberger et aI, 1976) and the conclusion that for most patients fixed dosage 
recommendations are inadequate (Burton et aI, 1985). 
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2.6.2 Predictive algorithms 
Based on studies illustrating the danger of using standard doses of theophylline and 
other studies demonstrating the large number of factors that affect theophylline 
clearance, dosing nomograms were developed (Koup et aI, 1976; lusko et aI, 1977). 
These nomograms predicted the dose needed to achieve a particular target serum 
concentration using information known about the patient such as presence of 
concurrent diseases (e.g. congestive heart failure or hepatic disease) and known 
pharmacokinetic characteristics of the drug. In 1980, the United States Food and 
Drug Administration published a nomogram with guidelines for aminophylline 
therapy. Due to its official status, these guidelines were largely accepted as the 
standard for a number of years. This is unfortunate since individualisation of 
therapy should have been the standard (Burton et aI, 1985). 
In general, predictive algorithms are useful as starting points but their inaccuracy 
limits their utility. This is because of the considerable variability in the population 
and the fact that most of these algorithms have been developed using small 
populations of patients, usually homogeneous groups (Burton et aI, 1985). They are 
usually most successful if used in the same population for which they were 
developed. 
Dosage algorithms that are currently popular are those of Hendeles et al (1980) for 
the determination of optimal intravenous theophylline doses for acute asthma and 
Hendeles et al (1978) for the determination of optimal theophylline dose for chronic 
asthma. A useful feature in both these nomograms is the guidelines on dose 
adjustment following serum theophylline concentration determination. 
2.6.3 Pharmacokinetic models 
Pharmacokinetic models were originally developed for use in formal 
pharmacokinetic studies to describe the behaviour of drugs in man. However, they 
can also be used in clinical pharmacokinetics to predict the serum drug 
concentrations that will result from a dosing regimen. 
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A number of pharmacokinetic methods have been used to individualise theophylline 
therapy. With all methods at least one serum theophylline concentration is 
measured and used to estimate an individual patient's pharmacokinetic parameters. 
Future dosing decisions are then based on these parameter estimates. 
A simple pharmacokinetic based method is the steady state clearance method of 
Slotfeldt et al (1979). In this method, the serum concentrations measured at the end 
of a continuous intravenous infusion of approximately 48 hours duration is assumed 
to be the steady state concentration. Clearance is then estimated using equation (1). 
Ri 
Cl = ( 1 ) 
CPss 
where Cl is the clearance in L/hr 
Ri is the rate of infusion in mg/hr 
CPss is the steady state concentration in ~g/rnl 
This method is simple to use and produces mean clearance values similar to those 
obtained using other available pharmacokinetic methods (Hurley and McNeil, 1988). 
However the obvious disadvantage is that this method can only be used in patients 
who have been administered intravenous therapy. 
A popular method is that of Chiou et al (1978) in which clearance is estimated from 
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equation (2) using data obtained during a constant intravenous infusion of 
theophylline. 
2 * Ri 
Cl = --------- + --------------------- ( 2 ) 
Cp, + CP2 
where lBW = ideal body weight (kg) 
Cp1 = post loading dose serum concentration (llg/ml) 
Cp2 = second serum theophylline concentration measurement obtained 4-6 
hours after the loading dose in children and smokers or after 8 hours in 
non-smokers (llg/ml). 
t1 and t2 = times at which CP1 and CP2 samples were drawn respectively (hr). 
The Chiou method accurately predicts theophylline dosage provided certain 
stringent requirements are fulfilled e.g. the infusion rate must be regulated by an 
infusion pump; the patient's elimination half-life is shorter than the time interval 
between the 2 measured samples (Hendeles and Weinberger, 1983) and laboratory 
precision must be excellent. Hurley and MeNeil (1988) found that the Chiou method 
gives accurate results only when the 2 serum concentrations were taken 11 - 17 
hours apart. 
Least squares estimation or fitting of a pharmacokinetic model to the data is the 
method most often used to obtain pharmacokinetic parameter estimates from a 
formal pharmacokinetic study. Using appropriately drawn samples, the method can 
be used to interpret routine clinical data. The least squares method is based on the 
well-known method of statistical estimation known as maximum-likelihood. 
An iterative computer method that uses the least squares estimation technique to 
individualise theophylline therapy has been described and evaluated (Mungall et at, 
1982). Mungall et al set a target serum theophylline concentration of 15 llg/ml, and 
the iterative computer method achieved 95% confidence intervals of 10.6 - 18.2 
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llg/ml with all patients achieving therapeutic concentrations. On the other hand, 
application of an empirical predictive algorithm achieved 95% confidence intervals 
of 3.3 - 28.5 llg/ml with only 7 of 15 patients achieving concentrations in the 
therapeutic range. 
An inherent problem with the least squares method and indeed with all the 
pharmacokinetic methods described above is their total reliance on serum level 
data. This means that no provision is made for comparison of the results with any 
prior expectations based on previous experience and known patient characteristics. 
This can potentially magnify the errors associated with inaccurate serum drug level 
determinations, resulting in large errors in parameter estimates. In order to provide 
accurate and precise estimates, multiple samples are necessary - at least equal to the 
number of parameters but preferably more. However, clinical realities preclude 
drawing multiple samples at kinetically optimal times. 
2.6.4 Bayesian approach 
The Bayesian approach (Sheiner et at, 1972) is a type of pharmacokinetic approach 
that is based on Bayes' theorem. It combines statistical probability and a weighting 
for each factor that may affect theophylline disposition, including the error involved 
in assaying the drug. 
The Bayesian method assumes that the chances of a pharmacokinetic parameter 
being different in an individual are the same as the variability observed in the 
population. Consequently, if the volume of distribution in the population is 
relatively constant with a small coefficient of variation, and clearance is more 
variable with a large coefficient of variation, the Bayesian re-estimation of the 
individual pharmacokinetic parameters will modify clearance more than volume of 
distribution. In addition, this method allows weighting for variability in the assay, in 
sampling and dosing time, in compliance to out-patient therapy, and in giving the 
most recent serum drug concentrations the most weight (Peck et aI, 1980). 
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If the accuracy of the data obtained is questionable or limited, a Bayesian method 
will analyse the data and identify a dosage somewhere between that which the 
population average and the serum levels would have predicted separately. If no 
serum theophylline levels are available then the population pharmacokinetic 
parameters serve as the starting point. In view of this, the Bayesian approach for 
initial drug dosage design may not be different clinically from any other well 
developed nomogram method . If, however, the population pharmacokinetic 
parameters are well defined, then this approach becomes a much more powerful 
clinical tool. Similarly as more of an individual patient's levels are obtained, their 
weighting increases and the population parameters become less significant (Frakes 
et aI, 1986). 
In this manner, Bayesian approaches attempt to combine many of the advantages of 
some previously discussed methods. Given adequate blood level data, the Bayesian 
approach will produce results as accurate as any other method currently in clinical 
use. 
Sheiner and Beal (1982) compared the Bayesian method with other pharmacokinetic 
based methods and found it to be significantly better than the others when assessing 
both accuracy and precision. Hurley and McNeil (1988) recently compared the 
accuracy of a least squares regression, a Bayesian, Chiou's and the steady state 
clearance method of Slotfeldt et al (1979) in individualisation of theophylline dosage 
(intravenous and oral) in 48 patients. They found the Bayesian method to be the 
easiest of the computer based methods to use. Since its accuracy was comparable 
with the other methods evaluated, they recommend it for clinical use. They note 
however, that "none of the methods evaluated were accurate in absolute terms" and 
suggest that clinicians regard pharmacokinetic parameters obtained with these 
methods to be estimates only. 
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2.6.5 CONCLUSION 
This report on theophylline dosing methods and interpretation of serum 
theophylline concentrations has traced the developments over the years with the 
culmination of the now widely accepted Bayesian approach. It has been noted that 
there is no ideal approach or perfect method. None of the methods guarantee 
clinical efficacy especially in the case of a changing clinical environment. All dosage 
changes made with any of the techniques outlined above should be made cautiously 
and the resulting serum theophylline concentrations checked. In view of its 
demonstrated accuracy, precision and ease of use, the Bayesian technique of drug 
dose optimisation is currently the preferred option. 
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Chapter Three 
Estimation of population pharmacokinetic parameters 
3.1 INTRODUCTION 
The axiom "Drugs don '( have doses - people have doses!' (Cipolle, 1986) is central to 
the motivation for population pharmacokinetic studies. Population 
pharmacokinetics describes the typical relationships between physiology, pathology 
and pharmacokinetics, the interindividual variability in these relationships, and 
their residual intraindividual variability. 
A knowledge of population pharmacokinetics can help one to choose initial drug 
dosage, to modify dosage appropriately in response to observed drug levels, to make 
rational decisions regarding certain drug regulatory requirements, and to investigate 
and elucidate research questions in pharmacokinetics (Sheiner, 1984). Its most 
important role thus far has been shown to be in therapeutic drug monitoring 
programmes that utilise the Bayesian forecasting technique. A prerequisite for 
satisfactory performance of this technique of drug dose optimisation is good 
estimates of the population parameter distributions. If these estimates are good, 
then the performance of the Bayesian system is improved (Whiting et aI, 1986). 
3.2 POPULATION PHARMACOKINETIC PARAMETERS 
There are 3 distinct types of popUlation pharmacokinetic parameters that are of 
interest to clinicians and researchers in pharmacokinetics :-
3.2.1 Fixed effects parameters 
These measure central tendency in the values of the essential pharmacokinetic 
parameters (Cl, Vd, Ka, F). The fixed effects parameters usually represent the mean 
values of the parameters and/or a number of parameters which describe these mean 
values as functions of various patient characteristics or pathophysiology e.g. age, 
smoking habits, body weight or liver function status. 
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3.2.2 Interindividual random-effects parameters 
In a population of individuals with a particular mean value for a fixed effect 
parameter, there exists a probability distribution about this mean value. The 
difference between any individual's parameter and the mean is referred to as the 
interindividual variability. A knowledge of the magnitude of this variability is useful 
in order to know to what extent the serum concentration will vary if an individual in 
the population is given some empirical dose of the drug in question. 
3.2.3 Intraindividual random-effects parameters 
Also referred to as residual variability. It explains all sources of variability that 
cannot be accounted for on the basis of the fixed effects and the interindividual 
variability. Thus the patient's day to day variability according to his biorhythms, 
assay error, model misspecification error, or any other variability are considered 
here. A knowledge of intraindividual variability is desirable in order to set 
reasonable thresholds for responding to changes in measured drug levels. 
3.3 TECHNIQUES FOR THE ESTIMATION OF POPULATION 
PHARMACOKINETIC PARAMETERS 
3.3.1 Traditional approach 
The subjects used as the source of data in the traditional approach to the 
determination of population pharmacokinetic parameters are a group of 10 - 30 
individuals selected so as to represent a spectrum of severity of a particular 
condition (Sheiner, 1984). For ethical reasons they are usually normal healthy 
volunteers or patients with lesser degrees of illness. The dosage schedule for the 
subjects is of simple design and the sampling times and number of samples (often 
more than 20 per subject) are the same for each individual. The design of these 
studies results in the provision of maximum information about individual kinetics. 
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The use of volunteers or patients with lesser degrees of illness and the small 
sample number means that the results obtained may not be representative of 
the patient population in whom the drug is eventually used therapeutically. 
The study is costly since, in addition to the expense involved in assaying a 
large number of samples, one has to consider the cost of temporary 
hospitalisation and compensation of volunteers. 
The rigid experimental protocol in which all study conditions are strictly 
controlled can actually prevent the discovery of unexpected but important 
influences on kinetics. 
The data generated by these studies are analysed using either the 'naive pooled 
data approach' or the 'two stage method' (Sheiner and Beal, 1980). In the naive 
pooled data approach, all the individuals' data are fitted together as though there 
were no individual kinetic differences. This method lacks popularity since it does 
not distinguish interindividual from intraindividual variability. Further in simulation 
studies, the parameter estimates have been found to be biased and less precise than 
those obtained by other means. In the more popular two stage method, the first 
stage involves analysing data from each subject to obtain estimates of the individual 
pharmacokinetic parameters. In the second stage, average parameter values are 
calculated and attempts may be made to quantitate the relationship between 
physiological and pathological factors and kinetic parameters. This method is also 
not ideal primarily because of the study design but also because parameter 
estimates tend to have an upward bias (Sheiner, 1984). 
Whiting et al (1986) in a review article on population pharmacokinetics state that the 
traditional methods of data analysis "have been thoroughly studied and are not, zn 
general, satisfactory". 
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3.3.2 NONMEM approach 
Sheiner et al (1972; 1977) recognised the above-mentioned handicaps of traditional 
pharmacokinetic studies and data analysis techniques. The novel approach of using 
data gathered directly from patients receiving the drugs of interest i.e. routine 
clinical data, was therefore introduced. In order to analyse such data, the concept of 
non-linear mixed effects modelling was developed and implemented in the form of 
the computer programme NONMEM. 
The NONMEM approach uses a statistical model in which individual patients' 
pharmacokinetic parameters are assumed to arise from a distribution which has a 
population mean and a particular quantifiable deviation from this mean. It can be 
seen therefore that the emphasis is shifted away from the individual patient to a 
system in which the population is treated as the unit of analysis. 
NONMEM describes the available data in terms of a number of fixed effect 
parameters denoted theta (8) and the two random effect parameters viz. the 
interindividual covariance matrix (n) and the variance, 0 2, of intraindividual and 
measurement error. The programme simultaneously derives fixed effects and 
random effects - hence the name mixed effects modelling. 
3.3.2.1 Statistical model 
The statistical model used by NONMEM to describe pharmacokinetic observations 
i.e. drug concentrations from N individuals, each with ni' i = 1, N observations, in 
terms of 8, nand 0 2 is described by equation (3). 
y .. = f(P . ,D . ,7 . ,t .. ,E .. ) 
lJ 1 1 1 lJ lJ ( 3 ) 
where Yij is the jth observation in the ith individual; f is a pharmacokinetic model 
(often involving a sum of exponentials); Pi is the vector of parameters of the model 
for the ith individual; Di is the dose administered and 7 i is the interval between 
doses - together they describe the entire dosing history of the individual from a point 
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in the suitably remote past up to and including time tij, the time of response; and the 
E; .. are independent identically distributed univariate random errors with mean zero 
IJ 
and variance 0 2• 
The Pi are further modelled in terms of population parameters according to 
equation (4). 
( 4 ) 
where q is a vector-valued function, Xi is the collection of all concomitant patient 
features (e.g. age, weight and smoking habits) relevant to predicting Pi' and the (\ 
are independent identically distributed multivariate random vectors with mean 
vector zero and covariance matrix Q. 
To estimate e, Q and 0 2, equation (4) is essentially substituted into equation (3), 
and the method of extended least squares (Beal, 1984) is applied. This method's 
objective function involves estimates of the expected value and variance of Yif The 
former can be expressed in terms of e only; the latter, in terms of e, Q and a . The 
parameter values yielding the minimum of the objective function are the extended 
least squares estimates (Sheiner and Grasela, 1984). 
3.3.2.2 Validation 
NONMEM relies on a precise statistical background; its theoretical basis has been 
investigated, and the statistical properties of the extended least squares estimate are 
well established (Steimer et aI, 1984). However, a true measure of its success is the 
numerous publications reporting on analysis of a number of commonly used drugs 
e.g. digoxin (Sheiner et aI, 1977), phenytoin (Sheiner and Beal, 1980; Grasela et ai, 
1983; Rheeders, 1985), gentamicin (Kelman et ai, 1984), procainamide (Grasela and 
Sheiner, 1984), mexiletine (Vozeh et ai, 1982, 1984) lignocaine (Vozeh et aI, 1984, 
1984a), warfarin (Mungall et ai, 1985), alfentanil (Maitre et ai, 1987) and 
metoclopramide (Grevel et ai, 1988). In these reports, dosing guidelines for specific 
patient sub-populations are determined and the influence of disease states on 
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pharmacokinetics are identified. Most reports comment on increased efficiency in 
dosage adjustment usually based on some form of subsequent feedback procedure -
most commonly one based on Bayes' theorem. 
3.4 CONCLUSION 
In the study of population pharmacokinetics, attempts are made to describe kinetic 
variability observed within groups of individuals by finding relationships between 
physiology, pathology and pharmacokinetics. Its most important role thus far has 
been in therapeutic drug monitoring programmes, particularly those that utilise the 
Bayesian system. Examination of available methods of analysing population 
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Chapter Four 
Evaluation of a new dry phase, strip immunoassay technique for analysis of serum 
theophylline concentrations 
4.1 INTRODUCTION 
The wide interpatient variability in elimination rates for theophylline, its narrow 
therapeutic index and the well documented relationship between serum 
concentration, clinical effect and toxicity are some of the important reasons for 
monitoring serum levels of this drug. 
Available assay methods for theophylline have been discussed in Chapter Two, 
Section 2.2. Recently, Ames Division, Miles Laboratories, Indiana have introduced 
the SeralyserR in South Mrica. This is a new analytical technique that combines an 
immunoassay with a dry chemistry procedure. The method utilizes a dry reagent 
contained on a plastic strip with a colorimetric indicator that is measured by a 
reflectance photometer. The Ames SeralyserR theophylline assay has been 
recommended as being suitable for small-volume work in places such as the 
physician's office and the emergency room (Cheung and Soldin, 1986). This would 
facilitate rational dosage adjustment based on serum concentrations while the 
patient waits in the doctor's consulting rooms . Other currently available 
methodologies have problems such as accuracy, prolonged time to process samples, 
size of sample required, complicated technology and high cost of system hardware 
and reagents, which limit their utility for this application (Lotner et ai, 1985). 
This study evaluates the analytical performance of the Ames SeralyserR against 
Abbott's TDxR. 
72 
4.2 MATERIALS AND METHODS 
4.2.1 Sample collection 
Over a 2 month period 52 samples were collected from 34 patients attending the 
Asthma Clinic at R K Khan Provincial Hospital. Venous blood was collected into 
plain glass tubes, allowed to clot and then centrifuged. Serum was separated and 
then an aliquot was analysed using the Ames SeralyserR housed in the Hospital's 
Pharmacy Department. The remainder of the serum was analysed using the 
Abbott's TDxR system at the University of Durban-Westville. Samples that could 
not be analysed immediately were stored at -20°C until analysis. Frozen samples 
were allowed to thaw at room temperature and were analysed within 7 days of 
collection. The concentration values obtained with the 2 instruments are recorded in 
Appendix A, Table At 
4.2.2 Sample analysis 
Ames Seralyse,R 
All components for the Ames SeralyserR system together with serum based 
standards (2.5 Jlg/ml and 25 Jlg/ml) and control (15 Jlg/ml) were supplied by Ames 
Division, Miles Laboratories, Indiana. 
Thirty microlitres of either standard, control or sample were diluted with 800 JlI of 
distilled water using fixed volume pipettes supplied by Ames. After thorough mixing, 
a 30 Jll aliquot was dispensed onto the reagent area of the test strip according to 
manufacturer's instructions. 
The rate of formation of a blue colour was measured at 740 nm by the SeralyserR,s 
reflectance photometer after 80 seconds. This rate of colour formation is 
proportional to the theophylline concentration. A calibration curve was constructed 
for each new batch of reagent strips or if the control results were greater or less than 
10% of their stated values. Calibration curves were stored in a removable Test 
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Module that formed part of the instrument and were used to calculate the 
theophylline concentration of samples and controls. The SeralyserR,s lower limit of 
assay detection is 3 llg/ ml. 
Abbott's TDxR 
All components for the Abbott's TDxR system for theophylline together with 
reagent packs, serum based standards and controls were obtained from Abbott 
Laboratories, Diagnostics Division, Irving, Texas. 
A minimum of 50 III of standard, controls or samples were pipetted or poured into 
sample cartridges. These were then placed into a carousel which has the capacity to 
accommodate 20 such sample cartridges. The carousel together with a theophylline 
reagent pack were placed into the TDxR Analyser and the batch assay process 
started as per manufacturer's instructions. All dilutions and subsequent sampling 
were performed automatically by the instrument. 
On each occasion, prior to analysis, the concentration of 3 known theophylline 
controls were measured. A new calibration curve was constructed whenever any of 
the 3 control results were greater or less than 10% of their stated values. The lower 
limit of detection at the 95% confidence limit is 0.5111g/ml. 
4.2.3 Data analysis 
The concentration measurements obtained using the 2 methods were analysed by 
linear regression analysis using the STATGRAPHICSR computer programme by 
Statistical Graphics Corporation available from the Computer Services Division, 
University of Durban-Westville. Graphs were generated using HARV ARD 
GRAPHICSR (Version 2.10, 1987), by Software Publishing Corp .. 
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4.3 RESULTS 
Theophylline concentrations ranged from 0.75 to 34.5 }J.g/ml. Eight samples were 
excluded from the comparative analysis because concentrations less than 3 }J.g/ml 
are not measurable by the SeralyserR technique. 
The linear regression equation for the best fit line with the SeralyserR (y) and TDxR 



































































































































































































During the 2 month evaluatiort period the TDxR was calibrated once only, while the 
SeralyserR needed to be recalibrated a total of 7 times (Table Ill). The total cost 
involved inclusive of calibrators and controls was as follows:-
Ames SeralyserR 
AbbottTDxR 
R804-28 (equivalent to R15-47 per sample) 
R706-68 (equivalent to R13-59 per sample) 
Table III - Comparison of SeralyserR with TDxR 
SeralyserR TDxR 
Number of batches of samples 11 11 
Number of calibration runs 7 1 
Number of calibrators used 14 12 
Cost per calibrator ' R2-78 RO-46 
Number of controls used 18 36 
Cost per control ' Rl-72 RO-31 
Number of samples analysed 52 52 
Total number of assays performed 14 + 18 + 53' = 85 12 + 36 + 52 = 
Cost per assay ' R8-64 R6-90 
Total cost to measure the 52 samples R804-28 R706-68 
Average cost R15-47 R1 3-59 
'Prices valid as at June 1989. 




In this study, the performance of the SeralyserR compared favourably and without 
bias with the more established TDxR. The regression equation with its slope of 1.057 
and intercept 0.078 was similar to values of slope = 1.083, intercept = -0.287, 
r = 0.98 (Cheung and Soldin, 1986) and slope = 1.05, intercept = 2.79 , r = 0.99 
(Vocich et ai, 1985) previously reported. These results closely approach the slope of 
1.00 and intercept of 0.00 required for perfect correlation of the two assay methods. 
Examination of Fig. 4 shows nearly equal scatter of data points on either side of the 
line of identity, indicating comparable results with either assay. 
Over the 2 month period, the SeralyserR required recalibration more frequently 
than the TDxR. The SeralyserR uses a 2 point calibration curve while the TDxR uses 
a 6 point curve in duplicate. The average cost of the assays was found to be higher 
for the SeralyserR (Table Ill). However, this may be partially offset by the fact that 
the capital outlay for the instrument itself is considerably lower. Other authors have 
found the cost per assay for the SeralyserR to be comparable to that of the TDxR 
and Syva Corporation's EMITR (Cheung and Sotdin, 1986). 
The minimum sample volumes required with both techniques is very similar viz. 
30 ~l for the SeralyserR and 50 ~l for the TDxR. The lower sample volume required 
with the SeralyserR is unlikely to be of any additional clinical advantage. 
While Vaughan et at (1986) found that the SeralyserR underestimates and produces 
variable results at concentrations less than 7.5 ~g/ml, these findings were not 
corroborated by this study. The inability of the SeralyserR to detect theophylline 
levels less than 3 ~g/rnl precludes its use in pharmacokinetic studies where it is 
important to be able to accurately and precisely measure concentrations at this 
level. However, these drawbacks are unlikely to be of clinical relevance in the 
applications for which this instrument is intended viz. for dosage adjustment in the 
emergency room or general practitioner's office. 
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4.5 CONCLUSIONS 
The performance of the Ames SeralyserR, a new dry phase strip immunoassay 
technique compares favourably and without bias with the established fluorescence 
polarisation immunoassay technique of Abbott's TDxR. The higher average cost of 
the assays with the Ames SeralyserR is probably offset by the considerably lower 
initial cost of the associated equipment. Its inability to detect serum levels < 3 
)J..g/ml precludes its use in pharmacokinetic studies. However, the method has 
sufficient sensitivity and speed to enable it to find a useful place in therapeutic drug 
monitoring in the emergency room or physician's office to handle low volume work. 
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Chapter Five 
The influence of the application of therapeutic drug monitoring on theophylline 
utilisation at R K Khan Hospital 
5.1 INTRODUCTION 
Prior to 1973, there was a paucity of information on appropriate theophylline 
dosage regimens or the therapeutic range in serum concentration for optimal 
therapy (Burton et aI, 1985). This situation changed when Mitenko and Ogilvie (1973) 
published their controversial recommendation of a standard intravenous infusion 
rate of 0.9 mg/kg/hr for all patients. This dosage regimen was later shown to result 
in clinical toxicity as well as serum drug concentrations greater than 20 }lg/ml in a 
large number of patients (Weinberger et aI, 1976; Kordash et aI, 1977; Hendeles et aI, 
1977), since it did not take into account the wide inter-patient variability in 
theophylline clearance. 
Subsequent reports of serious serum concentration related side-effects and toxicity 
(Hendeles and Weinberger, 1983; Fitzpatrick and Moss-Barclay, 1985) as well as 
inadequate serum concentrations and therapeutic failure (Jacobs et aI, 1976) with 
the use of standard doses of theophylline have been published. 
In an evaluation of Mitenko and Ogilvie's standard dose of aminophylline, Weinberger 
et aI, 1976 commented that "it is not possible to achieve optimal aminophylline dosage 
without monitoring serum theophylline concentrations". 
While serum concentration monitoring of the anti-epileptic drugs now appears to be 
well established in South Africa (Miller et aI, 1982; Klein et aI, 1986), the use of 
serum concentration monitoring to individualise theophylline dosage remains very 
limited despite widespread documentation of the potential improvement in patient 
care (Hendeles and Weinberger, 1980; Whiting et aI, 1984; Fitzpatrick and 
Moss-Barclay, 1985; Barlow et aI, 1988). 
81 
In 1986, one of the first local therapeutic drug monitoring programmes for 
theophylline was initiated at R K Khan Provincial Hospital, Chatsworth, Durban. 
This report evaluates the influence of this programme on theophylline utilisation at 
the hospital. It also considers the outcome of standard doses of theophylline 
administered to this population. 
5.2 MATERIALS AND METHODS 
5.2.1 Institutions 
The clinical study was conducted at the R K Khan Provincial Hospital in 
Chatsworth, Durban. This 680 bed hospital is under the control of the Department 
of Hospital Services of the Natal Provincial Administration. It caters primarily for 
members of the Indian population who provide an out-patient workload of 
approximately 1500 patients per working day. 
Serum theophylline concentration measurements and analysis of data were 
performed at the University of Durban-Westville, Durban. 
5.2.2 Patients/subjects 
Over a 2 year period, serum theophylline concentration measurements were 
performed on 181 patients. Ninety four patients were excluded from the study for a 
variety of reasons (see Table IV). The remaining 87 patients consisted of 49 females 
and 38 males, with an average age of 40.3 years and an average mass of 56.4 kg 
(Table V). All relevant data pertaining to patients included in the study are 
presented in Appendix B, Tables B1 to B5. These patients were categorised into 
groups (Table VI) on the basis of criteria detailed in this section. 
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Table IV - Patients excluded from the study. 
New patients I.e. seen within 1 month of this analysis. 14 
Records not available 10 
Transferred to another hospital 2 
Died soon after Initial consultation 
(1 * pancreatitis, 1 * acute exacerbation of 3 
asthma and 1 * motor vehicle accident) 
Less than 2 Interviews with the researcher 65 
Table V - Demographic details of the study population 
Sample number 87 
Age (yrs) average (SD) 40.3 (15.3) 
range 4.5 - 74 
Mass (kg) average (SD) 56 .4 (1 2.9) 
range 16 - 92 
Sex males 49 
females 38 
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Table VI - Classification of the study population 
Group 1 - Clinically controlled on initial dose 21 
Group 2 - NOT clinically controlled on initial dose 
2.1 Serum theophylline concentration > or = 15 ug/ml 5 
2.2 Serum theophylline concentration < 15 ug/ml 35 
Group 3 - Clinically toxic or potentially toxic 27 
Group 4 - Compliance problems 24 
NB: All groups are not mutually exclusive. 
GROUP 1 - Patients clinically controlled on their initial dose of theophylline. 
These are patients who were diagnosed by a pulmonologist to be stable or clinically 
well controlled and whose episodic exacerbations of asthma were rapidly relieved 
by inhaled beta-stimulants. In the majority of patients, the initial dose consisted of 
the manufacturer's recommendation of 1 sustained release tablet twice daily - either 
Euphyllin RetardR (256.1 mg) or TheodurR (200 mg or 300 mg). These doses had 
been prescribed prior to the initial consultation with the researcher. 
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GROUP 2 - Patients NOT clinically controlled on the initial dose of theophylline 
These patients, who received similar doses of theophylline as patients in GROUP 1, 
experienced frequent exacerbations of asthma symptoms that required emergency 
room treatment or hospitalisation. This group was further sub-divided into:-
GROUP 2.1 - Serum theophylline concentration ~ 15 }J.g/ml 
In this group of patients measurement of serum theophylline concentration at initial 
consultation recorded levels of approximately 15 }J.g/ml or more and further dose 
increases were considered potentially dangerous. 
GROUP 2.2 - Serum theophylline concentration < 15 }J.g/mi 
This group of clinically uncontrolled patients, formed the basis of a study to 
determine the influence of active intervention based on pharmacokinetic principles. 
The procedure followed in the pharmacokinetic assessment of patients on 
theophylline is outlined in a flow diagram (Fig. 5). All evaluations and dosage 
adjustments were performed in consultation with a pulmonologist. During 
consultation with the patient a questionnaire (Fig. 6) was completed by the 
researcher. At the initial consultation, compliance was assessed by means of careful 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Compliance was later assessed objectively by comparing measured theophylline 
concentrations with that predicted using average population pharmacokinetic 
parameters. Thereafter, dose individualisation was performed with the aid of a drug 
dose optimisation computer package, OPTR Version 4b, available from ClydesoftR 
Statistical and Scientific Software. This programme utilises the Bayesian feedback 
techniques previously described (see Section 2.6.4). 
These patients were followed for a period sufficient to determine therapeutic 
success or failure. To make an objective assessment, the patient's hospital records 




Frequency of emergency room visits and hospital admissions for acute 
exacerbations of asthma. The average number of visits per month over a 3 - 6 
month period prior to and after dosage review was recorded and evaluated 
using the sign test. 
Clinical evaluation of asthma symptoms at each clinic visit. 
Clinical evaluations were performed by the same pulmonologist throughout the 
period under review. 
GROUP 3 - Patients clinically toxic or serum theophylline concentration ~ 20 ~g/ml. 
Patients were diagnosed as clinically toxic if they experienced any of the generally 
accepted symptoms of theophylline toxicity such as nausea, vomiting, tachycardia, 
irritability, tremor or convulsions. They were considered to be potentially at risk of 
toxicity if their serum theophylline concentration was greater than 20 ~g/ml. 
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GROUP 4 -Patients with compliance problems. 
Patients were judged to be noncompliant if :-
* 
* 
they admitted to this during the interview, or 
evaluation of their serum theophylline concentration revealed a difference of 
more than 2 standard deviations from the expected concentration calculated 
using average population pharmacokinetic parameters. This was confirmed if 
subsequent serum concentration determinations recorded values consistent 
with prescribed doses. 
It was not possible to categorise patients into exclusive groups and therefore some 
patients appear in more than one category in Table VI e.g. 2 patients who improved 
clinically after they became compliant appear in Groups 2.2 and 4. However Groups 
1 and 2.1 are mutually exclusive. 
5.2.3 Statistical analyses 
The sign test used to evaluate the change in frequency of emergency room visits and 
hospital admissions was performed using the STA TIS2R Statistics Package (Version 
2.1, June 1987) available from ClydesoftR Statistical and Scientific Software. For 
statistical comparison the p < 0.01 level was regarded as significant. All other 
statistical analyses were performed using the STATGRAPHICSR computer 
programme by Statistical Graphics Corporation. Graphical illustrations of data were 
performed using the HARV ARD GRAPHICSR package (Version 2.10, 1987) by 
Software Publishing Corp .. 
The OPTR, HARVARD GRAPHICSR and STATIS2R programmes are licenced to 
the Department of Pharmacology while the University's Computer Services Division 
is the licencee for the STATGRAPHICSR programme. All software were used on 
IBMR compatible personal computers. 
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5.3 RESULTS 
The classification of patients into the relevant groups is presented below. Where 
applicable, results quoted are the average for the group with the standard deviation 
shown in parenthesis. A linear regression of dose on serum theophylline 
concentration is presented in Fig. 7. The regression analysis does not include 
patients who were non-compliant (Group 4). The equation for the line of best fit 
was y = 0.51x + 8.33 (R-squared = 6.46%). 
GROUP 1 - Patients clinically controlled on their initial dose of theophylline 
Twenty one patients (7 males and 14 females), i.e. 24% were clinically stable or 
well controlled on their initial dose of theophylline. These patients received an 
average dose of 9.6 (±2.5) mg/kg/day (range 4 - 15 mg/kg/day) theophylline. This 
dose resulted in an average serum theophylline concentration of 10.7 (±3.7) pg/ml 
(range 2.68 - 19.1 pg/ml). Six patients demonstrated serum theophylline 
concentrations less than 10pg/ml while 15 had levels between 10 - 20 pg/ml. 
GROUP 2.1 - Clinically uncontrolled - serum theophylline concentration ~ 15 pg/ml 
Five patients, 1 male and 4 females, average mass 62.7 (±20.3) kg who were 
clinically not controlled on their initial dose of theophylline were classified as being 
potentially at risk of theophylline toxicity, in the event of an increase in theophylline 
dose. The average dose of theophylline in this group was 9.96 (±3.73) mg/kg/day 
(range 5.8 - 16 mg/kg/day). Average serum theophylline concentrations of 16.3 
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GROUP 2.2 - Clinically uncontrolled - serum theophylline concentration < 15 }J.g/ml 
Thirty five patients (18 males, 17 females) had serum theophylline concentrations 
less than 15 }J.g/ml and poor control of their asthma. Six months after dose 
individualisation as described, 24 (68.6%) patients were judged to have improved 
clinically. This was shown to be statistically significant for the group (sign test p < 
0.00001). In 5 patients, this decision was based solely on the clinical evaluation 
conducted by the pulmonologist and researcher during the patient's monthly visit to 
the Asthma Clinic. In the remaining 19 patients, clinical improvement was 
associated with a decrease in the frequency of emergency room visits (sign test p < 
0.00001; see Fig. 8). In 11 of these 19 patients, a decrease in the number of hospital 
admissions was also noted (sign test p < 0.001; see Fig. 9). 
Five of the 24 patients required regular oral prednisolone in addition to the 
individualised theophylline dose. Exclusion of these 5 patients from analysis still 
revealed a statistically significant decrease in emergency room visits (sign test 
p < 0.0001) and hospital admissions (sign test p < 0.002). 
In 2 patients previously on steroids, theophylline dose individualisation resulted in a 
decrease in steroid requirement. In the one patient steroid requirement was 
decreased by 67% while in the other, steroids were stopped completely. A further 
two patients improved clinically after they became compliant and required no 
theophylline dose adjustment. 
The 11 patients (31.4%) not controlled after individualisation of theophylline dose 
were found to be severe steroid dependent asthmatics. Three patients showed poor 
reversibility of their bronchospasm as evidenced by a poor response to a short 
course of high dose steroids. In one patient her environment aggravated her 
symptoms while another two experienced serious social problems that contributed 
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GROUP 3 - Patients clinically toxic or serum theophylline concentration > 20 l1g/ml 
Details of the 27 patients (13 males, 14 females) exhibiting theophylline toxicity or 
potential toxicity are listed in Table VII. 
Table VII - Possible reasons for theophylline 
toxicity 
Sample number 27 
Drug - disease interaction 
CHF 10 
Liver function impairment (inferred from alcohol abuse) 2 
Drug - drug interaction 
erythromycin 2 
cimetidine 1 
Age related decrease in clearance 10 
Concurrent intravenous and oral therapy 
No apparent / obvious reason 
NB: Classification is not mutually exclusive 
These patients, average mass 55.8 (± 15.2) kg received an average dose of 
10.22 (±5.4) mg/kg/ day. Serum theophylline concentrations averaged 
25.4 (±6.3) l1g/ml (range 17.36 - 42 l1g/ml). Eighteen patients displayed signs of 
theophylline toxicity which varied from mild symptoms of nausea, vomiting and 





In one patient a serum theophylline concentration of 16.5 J..Lg/ml was measured 24 
hours after the patient had experienced a seizure while being infused with 
aminophylline at the emergency room. Using available dosing information it was 
possible to estimate her serum theophylline concentration at the time of the seizure 
by means of Bayesian statistics as approximately 30 J..Lg/ml. This value was used in 
subsequent statistical analyses of the group as it reflects the approximate serum 
theophylline concentration at the time of the toxic manifestation. All other values 
used were those actually measured. A drug-disease interaction was the possible 
reason for toxicity in 12 patients, while in 3 cases, a drug-drug interaction was 
identified. In 10 occurrences of toxicity (age > 60 years), the decrease in 
theophylline clearance that occurs with age possibly accounted for the toxicity. 
Five patients experienced toxicity subsequent to concurrent intravenous and oral 
therapy, of which 2 were due to inadvertent continuation of oral therapy after 
institution of intravenous aminophylline. In the other 3 (1 seizure), toxicity occurred 
during treatment at the emergency room with standard doses of aminophylline. 
In 2 cases, no obvious reason for theophylline toxicity could be identified. 
GROUP 4 - Patients with compliance problems 
Non-compliance was detected in 24 patients (28%, 14 males and 10 females). This 
consisted of 19 cases of under-dosing, 4 cases of over-dosing and in one patient both 
on different occasions. Eleven patients admitted to being non-compliant on 
interview while in the remaining 13 patients, non-compliance was ascertained only 
after the measurement of serum theophylline concentrations that were inconsistent 
with predicted concentrations using average population pharmacokinetic 
parameters. In all these patients this conclusion was confirmed when repeat analysis 
produced serum concentrations that were consistent with the prescribed dose. 
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5.4 DISCUSSION 
In any clinical situation that requires titration of drug dose to a desired therapeutic 
endpoint, the ideal is to have a close correlation of dose to effect (Burton et aI, 
1985). Unfortunately this ideal is not realised in the case of theophylline. Three 





dose-clinical effect relationship 
dose-serum concentration relationship 
serum concentration-clinical effect relationship 
The average dose of 9.6 mg/kg/day administered to the patients who achieved 
clinical control on their initial dose (Group 1), does not differ markedly from the 
10.22 mg/kg/ day dose administered to the patients who experienced theophylline 
toxicity (Group 3), or the dose of 10.03 mg/kg/day in the patients who were not 
controlled on their initial dose (Group 2). This implies a poor relationship between 
dose and clinical effect. 
The linear regression of dose on serum theophylline concentration (Fig. 7), shows a 
large scatter of data points and a coefficient of determination (r2) of 6.46%. This 
indicates that a very small percentage of the variation in the data can be explained 
by the regression line. This implies a poor relationship between dose and serum 
theophylline concentration. Hendeles et al (1977) found a similar large variability in 
serum drug concentrations relative to dose in 48 subjects given high doses of 
aminophylline by constant infusion. 
On the other hand, a relationship between serum theophylline concentration and 
efficacy is now well established (Mitenko and Ogilvie, 1973; Levy and Koysooko, 
1975). However, this may sometimes have the effect of shifting the emphasis away 
from achieving clinical control to a situation in which a serum theophylline 
concentration within the therapeutic range is sought. Indeed, most studies in the 
past have measured the utility of therapeutic drug monitoring in terms of the 
achievement of a 'therapeutic' serum theophylline concentration (Whiting et at, 
1984; Fitzpatrick and Moss-Barclay, 1985). 
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The present study has highlighted the advantages of measuring clinical response 
directly, if at all possible. Of the 49 patients in Groups 1 and 2 with serum 
theophylline concentrations within the generally accepted therapeutic range (10 - 20 
}.lg/rnl) , only 33 (67%) were well controlled. It is clear therefore, that clinical 
improvement is a better measure of satisfactory treatment with theophylline, 
although the achievement of therapeutic serum theophylline concentration provides 
a useful guide to therapy. 
Examination of the serum theophylline concentrations achieved in the 21 patients 
who were clinically stable on the initial dose (Group 1) reveals that while the 
majority of patients (71%) had serum theophylline concentrations within the 
therapeutic range, 6 patients were controlled at serum levels below 10 }.lg/rnl. This 
then serves to emphasize the need to view the therapeutic range as a statistical 
concept with respect to group means, within which individuals differ both in efficacy 
and side-effects (Jenne, 1984). 
The advantage of therapeutic drug monitoring in this context is that it eliminates the 
uncertainty in the relationship between the dose and the serum theophylline 
concentration in an individual. Further, it allows one to predict the likelihood of 
producing therapeutic effects or potential toxicity with any dose change. 
Classification of patients into Group 2.1 attempts to identify possible theophylline 
treatment failures. The criterion not to increase theophylline dosage if the level is 
greater than 15 }.lg/rnl is unique to this clinic and was considered in the best 
interests of the patient. The need to be conservative relates to a practical problem 
observed with respect to theophylline dosing patterns in the emergency room. Here 
patients who present with acute asthma are given a standard loading dose of 250 mg 
of aminophylline irrespective of whether there is a history of prior therapy with 
theophylline in the previous 24 hours. If one assumes an average Vd of 0.5 L/kg 
then each mg/kg dose of theophylline will result in a 2 }.lg/rnl increase in serum 
theophylline concentration. Since the average mass of this population is 56.4 kg then 
a standard loading dose of 250 mg aminophylline (3.79 mg/kg theophylline) should 
give an average increase in the serum concentration of approximately 7 }.lg/ml. A 
patient with an average serum theophylline concentration of 15 }.lg/rnl therefore can 
be expected to have an increase in this level to ±22 }.lg/rnl hence being potentially at 
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risk of toxicity. These mathematical projections are validated by the observation that 
3 of the patients in Group 3 became toxic after administration of the standard 
loading dose in the emergency room. In view of this problem, the emergency room 
dosing regimen was the subject of a prospective evaluation in 31 asthmatics (see 
Chapter Six). 
A major difficulty in evaluating the clinical efficacy of any therapeutic regimen in 
asthma results from the variable and unpredictable nature of the disease itself and 
because it is precipitated by many factors. The decision to use frequency of 
emergency room visits and hospital admissions as the main criterion in assessing 
control is based on the recommendation of Bredon et al (1985). A major drawback is 
that this tends to place more emphasis on the severe attacks of asthma while not 
detecting a chronic level of bronchospasm that the patient may have. This chronic 
level of bronchospasm may severely restrict the quality of life of the patient. In 
order to overcome this drawback the patient's subjective symptoms were also 
assessed, both by the pulmonologist as well as the researcher in the monthly 
evaluation of the patient. Although observer bias could not be excluded completely 
in this assessment, this was kept in mind during the retrospective analysis ant a 
patient was only judged to have improved if both the researcher's and the 
pulmonologist's assessments concurred and if there was a definite indication by the 
patient of an improvement in the quality of life. 
The results in Group 2.2 have clearly shown that in asthmatics who do not achieve 
satisfactory clinical control with a standard dose of theophylline, it is possible to 
increase and individualise the dose with significant additional clinical benefit. Such 
increases in dose should be guided by serum concentration measurements in order 
to ensure concentrations in the safe therapeutic range. This observation echoes that 
of numerous other authors (Hendeles and Weinberger, 1980; Whiting et aI, 1984; 
Fitzpatrick and Moss-Barclay, 1985; Barlow et aI, 1988). However, the results of this 
study are particularly encouraging in view of the fact that patients attending the 
Asthma Clinic at R K Khan Hospital may be considered to be a 'survivor 
population' of asthmatics attending the hospital. These patients are only admitted to 
the Asthma Clinic after experiencing an acute exacerbation of asthma that was 
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severe enough to warrant hospital admission. In general, when seen at the Clinic for 
their initial consultation they have already been prescribed all available anti-asthma 
medications. 
In the 11 patients in Group 2.2 who did not improve after theophylline dose 
individualisation, attempts were made to find the reason for their poor response. 
While information about poor reversibility of the airways are easily obtained, 
reasons such as psychosocial problems are much more difficult to assess. These 
physical manifestations of the many stresses and conflicts that the patient is 
experiencing would probably benefit more from a trial of 'warmth and 
understanding' (Peck and King, 1985) than an individualised dose of theophylline. 
The clinical symptoms of theophylline toxicity are well documented, as is the 
correlation of serum concentrations with toxicity (Zwillich et aI, 1975; Hendeles et aI, 
1977). The decision to classify patients with serum theophylline concentrations 
greater than 20 }lg/ml into Group 3 despite the absence of clinical symptoms of 
toxicity was based on an observation by Hendeles and Weinberger (1983). 
Commenting on the Zwillich study, they noted that minor symptoms of toxicity such 
as nausea and vomiting do not always precede severe life-threatening toxicity and 
that only serum theophylline concentration measurements can reliably forewarn the 
physician of such an eventuality. 
Examination of the possible reasons for toxicity in the 27 patients in Group 3 
(Table VII) reveals that in many cases, this toxicity could have been avoided if 
pharmacokinetic considerations had guided the choice of initial dose. Ten patients 
with congestive heart failure received the same standard dose as the otherwise 
healthy, 'normal' patients. Several reports have described a decrease in theophylline 
clearance in patients on theophylline therapy who develop congestive heart failure 
e.g. Hendeles et al (1986) warn that" the decrease in theophylline clearance can be 
quite large and of major clinical significance". While the mechanism for altered 
theophylline metabolism is unknown, at least 3 possible explanations have been 
proposed. These have been alluded to in Chapter One, Section 1.5.3.1.3. 
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In 2 patients, toxicity was due to the concurrent administration of erythromycin, an 
enzyme inhibitor. While this interaction has been widely reported (Prince et ai, 1981; 
LaForce et ai, 1981), it is this researcher's observation from this study that 
prescribers consider it to be clinically insignificant. This probably relates to the fact 
that theophylline is often prescribed in doses that result in sub-therapeutic serum 
concentrations in a large percentage of the population. Administration of 
erythromycin in these patients merely results in the serum theophylline 
concentration being increased to within the therapeutic range. However, toxicity 
may occur if the patient's serum theophylline concentration is in the upper level of 
the therapeutic range. 
In another patient, potential toxicity was due to the concurrent administration of 
another enzyme inhibitor, cimetidine. This drug interaction which may result in 
rapid decreases in theophylline clearance (within 24 hours) is reported to have been 
the cause of at least one fatality (Hendeles et ai, 1986). The interaction is clinically 
important since the two drugs are often prescribed concurrently to patients in 
intensive care units who have gastrointestinal bleeding and who are intubated and 
being maximaUy bronchodilated. In this patient, the alternate H2 receptor 
antagonist, ranitidine was substituted and the serum theophylline concentrations 
subsequently decreased. 
In 2 patients, toxicity occurred following overcompliance with oral theophylline. 
These patients experienced poor control of their asthma and in an attempt to obtain 
relief from their bronchospasm, unwittingly increased the dose and frequency. Their 
overcompliance is consistent with observations that patients with poor control of 
symptomatic conditions (e.g. arthritis) frequently tend to self-medicate leading to 
overdosage (Kubacka and Juhl, 1985). 
Non-compliance with medical regimens is a major obstacle to the provision of 
adequate medical care. It is a particular problem in therapy with long term 
prophylactic regimens. A review by Sackett and Snow (1979) suggests that 20 - 30% 
of patients fail to follow short term medication regimens when the regimen is 
curative, and 30 - 40% of patients when the regimen is preventative. In long term 
regimens, non-compliance rates average about 50% and increase with time. 
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The results of this study (28% non-compliance) are in general agreement with the 
above-mentioned observations. Theophylline is a prophylactic in the management of 
asthma. Therefore, one can expect occasional under-compliance in a patient who 
either experiences good control with this agent or who has episodic exacerbations of 
asthma. Another problem that has been identified by this study is that of 
over-compliance (4 patients - 2 of whom became toxic), particularly in those 
patients who experience poor control. It is envisaged that the role of therapeutic 
drug monitoring would be to identify these patients, who would then be counselled 
and/ or prescribed additional anti-asthma medications. 
5.5 CONCLUSIONS 
From the results of this study, it may be concluded that :-
1. A poor correlation exists between theophylline dose and clinical effect. 
2. A poor relationship exists between theophylline dose and serum 
concentration. 
3. While a good correlation exists between therapeutic serum theophylline 
concentration and clinical efficacy, this is not absolute - some patients are 
well controlled at so-called sub-therapeutic concentrations. 
4. In patients who do not achieve satisfactory clinical control with the 
manufacturer's recommended initial doses of theophylline, and who have 
serum concentrations considered to be sub-therapeutic, it is possible to 
increase and individualise the dose with significant clinical improvement. 
Such dosage adjustments should be guided by serum concentration 
measurements. 
5. Theophylline related toxicity could probably be reduced if dosage is guided 
by consideration of the many factors that influence theophylline clearance. 
6. Serum theophylline concentration measurements are a useful guide to the 
objective assessment of patient compliance. 
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Chapter Six 
Evaluation of the use of a standard fixed dose of theophylline in the emergency 
room management of acute asthma 
6.1 INTRODUCTION 
It is common practice at R K Khan Hospital to administer a standard intravenous 
dose of 250 mg aminophylline (equivalent to 214 mg theophylline) to patients with 
acute asthma irrespective of body mass or history of prior intake of theophylline. It 
has been recommended, however, that theophylline loading dose should be 
calculated taking these factors into consideration (Hendeles and Weinberger, 1981). 
Hendeles et al (1980), suggest that a dose of 5 mg/kg is an appropriate loading dose 
in a patient who has not received any theophylline-containing medications in the 
previous 24 hours, while in a patient who has taken some theophylline, a dose of 
2.5 mg/kg is considered to be relatively safe, provided the patient does not already 
have symptoms of theophylline toxicity (HWJ dose). 
The motivation for this study was the finding that patients given the fixed dose of 
250 mg aminophylline experienced severe life-threatening seizures (1 patient) or 
serum theophylline concentrations greater than 20 }.lg/ml (2 patients) - see Chap[ter 
Five. 
In this study no attempt is made to correlate clinical control with serum 
theophylline concentrations. The primary purpose of this study was to determine 
how often therapeutic or toxic concentrations were obtained with the standard 
dosing regimen prescribed at R K Khan Hospital and to compare this with 
concentrations expected if the dose as recommended by Hendeles et aI, 1980 had 
been used. 
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6.2 MATERIALS AND METHODS 
Over a 6 month period, 35 patients presenting to the emergency room between 
16h30 and 21hOO with an acute exacerbation of asthma were included into the study 
depending on the availability of the researcher. 
After clinical assessment by the casualty medical officer, patients were transferred 
to the emergency treatment room where nursing staff administered the following 
standard treatment protocol as authorised by the casualty medical officer :-
Salbutamol nebulisations 
Hydrocortisone 200 mg intravenous injection 
Aminophylline 250 mg in 200 ml normal saline infused 
over approximately 2 hours (the RKK dose). 
After completion of treatment a blood sample was drawn at a time not less than 
thirty minutes after cessation of the theophylline infusion. Samples were drawn by 
venipuncture on the arm opposite to that in which the infusion was administered . 
These were then centrifuged and the serum stored at -20°C until ready for analysis 
with either the EMITR or TDxR methods. 
When the acute phase of the attack was over, the patient was interviewed by the 
researcher and a questionnaire was completed (Fig. 6, Chapter Five). If at this stage, 
potentially high serum theophylline concentrations were suspected based on 
available information and average population pharmacokinetic parameters, then it 
was recommended to the casualty medical officer that theophylline therapy be 
terminated. 
The estimated serum theophylline concentration that would have been achieved 
with the Hendeles et aI, 1980 recommended dose of 2.5 or 5 mg/kg depending on 
history of theophylline use in the previous 24 hours was calculated proportionately 
from the measured serum concentration and mg/kg dose in the individual patient 
using equation (5). 
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where CpHWJ is the estimated serum theophylline concentration if the HWJ dose 
had been used. 
Cp is the measured serum theophylline concentration in }lg/ml. meas 
DoseHWJ is the mg/kg HWJ dose previously described . 
Doseadmin is the mg/kg RKK dose administered. 
All relevant data pertaining to the patients included in this study are recorded in 
Tables Cl to C3, Appendix C. 
6.3 RESULTS 
The 35 patients (22 males, 13 females) included in the study had an average age 
of 36.8 (±11.4) years (range 16 - 65 years) and average mass of 58.6 (±9.4) kg (range 
43 - 89 kg) - see Table VIII. 
Four patients (all males) did not respond to an initial course of treatment. These 
patients were reviewed by the casualty medical officer who prescribed an additional 
dose of aminophylline (250 mg) and further nebulisations with salbutamol. 
Measurement of serum theophylline concentrations 30 minutes after completion of 
this second infusion revealed that 3 patients had levels within the therapeutic range 
and 1 patient a level greater than 20 )lg/ml. 
Of the remaining 31 patients, 14 patients (45%) achieved serum theophylline 
concentrations less than 10 )lg/ml, 12 patients (39%) had concentrations between 
10 - 20 )lg/ml and concentrations greater than 20 )lg/ml were recorded in the 
remaining 5 patients. 
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Table VIII - Demographic details of the study 
population 
Sample number 35 
Age (yrs) average 36.8 (11.4) 
range 16 - 65 
Mass (kg) average 58.6 (9.4) 
range 43 - 89 
Sex males 22 
females 13 
All values quoted are average (SD) 
In two patients, the infusion was stopped before completion - 1 due to side-effects 
(severe nausea and vomiting - serum theophylline concentration 8.05 J.lg/ml) and 
another because of suspected high serum levels. The latter patient admitted to 
over-compliance with oral theophylline prior to admission to the emergency room. 
Using average population pharmacokinetic parameters his serum theophylline 
concentration was estimated to be approximately 25 J.lg/ml. Subsequent 
measurement after cessation of intravenous therapy recorded a level of 22 J.lg/ml. 
Since complete emergency room dosing information was not available for these 2 
patients, the expected serum theophylline concentration with the HWJ dose was 
not calculated. 
In the 33 patients in whom the calculation was performed, the results indicate that 
11 patients (33%) would have had levels below the range, 20 (61 %) patients within 
the range and 2 patients (6%) would have had serum theophylline concentration 
greater than 20 J.lg/ml (Table IX). 
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Table IX - Comparison of serum theophylline 
concentrations obtained using the RKK loading dose 
with that expected using the HWJ dose. 
<10 ug/ml 10-20 ug/ml >20 ug/ml 
RKK DOSE n = 35 
Patients given 1 dose of aminophylline 14 12 5 
Patients given 2 doses of aminophylline 0 3 1 
Total 14 (40%) 15 (43%) 6 (17%) 
HWJ DOSE n = 33' 
2.5 mg/kg theophylline 8 13 2 
5.0 mg/kg theophylline 3 7 0 
Total 11 (33 %) 20 (61 %) 2 (6 %) 
, Calculation not done in 2 patients due to incomplete dosing information 
6.4 DISCUSSION 
The average RKK dose of 3.65 mg/kg theophylline administered to this population 
(average mass 58.6 kg) can be expected to increase the serum theophylline 
concentration by approximately 7 }.lg/ml if one assumes an average volume of 
distribution of 0.5 L/kg. The HWJ recommended dose of 2.5 or 5 mg/kg is expected 
to increase the concentration by 5 or 10 }.lg/ml respectively. 
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While the RKK dose has been shown to be typically conservative (40% with levels 
below the range and 43% within the range), it is noteworthy that 6 patients (17%) 
had serum theophylline concentrations greater than 20 ~g/ml after administration 
of the first dose of aminophylline. 
Under ideal circumstances, serum theophylline concentration measurements should 
be performed prior to the administration of a loading dose if there is a history of 
theophylline use in the previous 24 hours (Hendeies and Weinberger, 1981). This was 
not possible in the present study since the necessary equipment was not available at 
the hospital - all serum theophylline concentration determinations being done at the 
University of Durban-Westville, 25 km away. If dosage had been guided by serum 
theophylline concentration determinations in these patients, then it is envisaged that 
more patients (if not all) would have achieved serum theophylline concentrations in 
the therapeutic range. In addition, the patient who had been over-compliant with 
his out-patient prescription of oral theophylline would have been identified earlier 
and not subjected to the potential risks of high serum theophylline concentrations 
and toxicity. 
Despite the absence of facilities to measure stat theophylline levels, the results of 
this study indicate that the use of a mg/kg loading dose of theophylline 
individualised on the basis of the history of prior theophylline use will produce 
satisfactory concentrations in 61 % of patients. This is not entirely surprising since 
the calculation of loading doses requires a knowledge of the volume of distribution, 
which in the case of theophylline does not exhibit as much inter-individual 
variability as does clearance (Hendeies et ai, 1986). One can therefore administer 
the same mg/kg loading dose of theophylline to a heterogeneous group of patients 
with a minimum of variation in the serum theophylline concentrations. 
A possible explanation for the nausea and vomiting experienced by the patient with 
a relatively low serum theophylline concentration of 8.05 ~g/ml may have been an 
unintended faster than normal infusion rate. Excessively rapid intravenous 
administration results in transiently high serum concentration, because of the finite 
time required for distribution from the central compartment into the whole-body 
theophylline distribution space (Hendeies et ai, 1986). 
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6.5 CONCLUSIONS 
A standard fixed dose of theophylline administered to patients irrespective of body 
mass or history of prior intake of theophylline has resulted in serum theophylline 
concentrations ranging from sub-therapeutic to potentially toxic. 
Dosing according to body mass and history of theophylline use results in calculated 
serum theophylline concentrations that are much more acceptable in terms of the 
therapeutic range. 
The recommended doses of 2.5 mg/kg for a patient who has ingested theophylline 
in the previous 24 hours and 5 mg/kg for the patient who has not, appears to be 
satisfactory in the majority of patients. 
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Population pharmacokinetics of theophylline 
7.1 INTRODUCTION 
Good therapeutic practice should always be based on an understanding of 
pharmacokinetic variability. This ensures that dosage adjustments can be made to 
accommodate differences in pharmacokinetics due to genetic, environmental, 
physiological or pathological factors (Whiting et aI, 1986). 
The introduction of the NONMEM computer programme has facilitated the 
identification of circumstances in which the above factors are important and has 
enabled a quantification of pharmacokinetic variability using routine clinical data 
(Sheiner et aI, 1972). The purpose of this study was to apply the NON ME M 
approach to determine the pharmacokinetics of theophylline in an Indian 
population. This information is currently not available. In addition to ascertaining 
any differences in pharmacokinetic parameters compared to other populations 
previously studied, the estimates obtained from this analysis may be used in 
Bayesian forecasting computer programmes to increase the accuracy of dosage 
predictions for this population. 
To this end, theophylline pharmacokinetic parameters and the degree of inter- and 
intra-individual variability were determined in a smoking and a non-smoking 
population. Two separate sets of data were used in this study. In Study 1, data from 
a traditional pharmacokinetic investigation was used i.e. a rigid protocol, small 
number of volunteers and many samples per subject; while Study 2 can be regarded 
as consisting of typical routine clinical data. In view of the difference in the study 
protocols, they were analysed separately in the NONMEM programme. 
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7.2 MATERIALS AND METHODS 
7.2.1 Subjects and patients 
7.2.1.1 Study 1 - Traditional Pharmacokinetic Study 
This data was derived from a multi-centre comparative bioavailability study done on 
smokers and non-smokers. The preparations investigated were Euphyllin RetardR 
tablets, TheodurR 300 mg tablets and AlcophyllinR elixir. 
The smokers were a group of 12 otherwise healthy volunteers, 9 men and 3 women 
with an average mass of 73.40 (± 13.99) kg, range 48 to 97.5 kg and average age 36.4 
(±11.3) years, range 22 to 60 years. All of the subjects smoked more than 15 
cigarettes per day. This part of the study was conducted by Miller and associates at 
the Department of Pharmacology, Potchefstroom University for CHE, 
Potchefstroom, Transvaal in 1984 and is hereafter referred to as the PUCHE data 
(Miller and Rheeders, 1984). 
The non-smokers were a group of 11 otherwise healthy male volunteers with an 
average mass of 78.2 (± 10.1) kg, range 69.5 to 105 kg and average age of 20 years. 
This part of the study was conducted by Straughn and associates at the Department 
of Pharmacology, University of Cape Town, Cape and is hereafter referred to as the 
UCTdata. 
All relevant data pertaining to the subjects included in this study are recorded in 
Tables Dl to D12, Appendix D. 
7.2.1.2 Study 2 - Routine Clinical Data 
The data for this study (referred to as the RKK data) was collected between 1986 
and 1988 at the R K Khan Provincial Hospital in Chatsworth, Durban during 
routine clinical consultations at the Asthma Clinic. 
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The following patients were excluded from the NONMEM analysis:-
* Patients with concomitant illnesses known to affect theophylline clearance 
e.g. congestive heart failure, liver disease or febrile illnesses. 
* Patients who had recently been treated with any drug known to alter 
theophylline clearance e.g. cimetidine, erythromycin or phenobarbitone. 
* Patients less than 20 or greater than 40 years of age. 
* Patients with a known compliance problem in whom the dosing history was 
considered to be unreliable. 
The RKK data set consisted of 30 patients (12 males, 18 females), age 30 (±5) years, 
range 21- 39 years; mass 58 (±11) kg, range 36.9 - 80.5 kg. The group consisted of 10 
smokers (all males) and 20 non-smokers. All relevant data pertaining to these 
patients are recorded in Tables D13 to D15, Appendix D. 
7.2.2 Dosing regimen and sampling times 
7.2.2.1 Study 1 - Traditional Pharmacokinetic Study 
Subjects received TheodurR (Rio Ethicals), Euphyllin RetardR (Byk Gulden) and 
AlcophyllinR elixir (Prop an Lipworth) in a randomised fashion during 3 consecutive 
weeks. AlcophyllinR 30 rnl (anhydrous theophylline 160 mg) was given three times 
daily at 08hOO, 14hOO and 20hOO, while TheodurR (anhydrous theophylline 300 mg) 
and Euphyllin RetardR (anhydrous theophylline 256.1 mg) were given twice daily at 
08hOO and 20hOO. All 3 products were administered for 4 days, with blood samples 
being drawn prior to dosage on day 1. On day 4, blood samples were drawn at 0, 0.5, 
1, 2, 3, 4, 6, 8, 12, 24, 27 and 33 hours after administering tablets and 0, 0.25, 0.5, 
0.75, 1, 1.5,2,2.5,3,4,6, 8, 12, 14,27, and 33 hours after administering elixir. 
Exclusion of some data points: Examination of the theophylline plasma 
concentration - time data revealed the presence of a significant lag time in 
absorption of the tablets. This was particularly prominent for TheodurR. At present 
NONMEM'S PREDPP package does not have an appropriate means of 
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determining lag time (Beal, 1985) and therefore, various time points during the 
absorption phase corresponding to a possible lag time were omitted. The absorption 
rate constant (Ka), determined using this data, is therefore an average from the time 
of administration. 
7.2.2.2 Study 2 - Routine Clinical Data 
In the routine clinical study, subjects received either TheodurR or Euphyllin 
RetardR on an out-patient basis. The average dose of TheodurR was 10.17 (±2.28) 
mg/kg/day (range 5.23 to 16.67 mg/kg/day) and Euphyllin Retard 10.41 (±3.80) 
mg/kg/day (range 6.61 to 20.81 mg/kg/day). With the exception of 1 patient who 
received doses 8 hourly, all other doses were administered on an approximate 12 
hour schedule. Blood samples were drawn at steady state and not less than 4.0 hours 
after the last oral dose. The 30 individuals included in the study had a total of 58 
dose-concentration pairs, 6 patients had 3 pairs each, 10 had 2 and in 12 patients, 
there was only one dose-concentration pair each. 
7.2.3 Theophylline serum concentration analysis 
In Study 1, serum theophylline concentrations were measured using the EMITR 
technique, while in Study 2, samples were measured using either the EMITR or the 
TDxR systems. 
7.2.4 NONMEM Analysis 
The population pharmacokinetic analysis was performed on a mainframe computer 
(ICL2988) at the University of Durban-Westville using Double Precision 
NONMEM 77 - version 11 level 1.4 together with the PREDPP package (ADV AN 2, 
TRANS 2 AND SS2) (Beal and Sheiner, 1980 -1986). 
A one compartment linear pharmacokinetic model with first order absorption was 
implemented by choosing the ADV AN 2 subroutine provided in the 
NONMEM-PREDPP load module. The use of the subroutine TRANS 2 makes it 
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possible to estimate the pharmacokinetic parameters, clearance (Cl) and volume of 
distribution (V d) while the model in PREDPP operates with the parameters, 
elimination rate constant (K) and absorption rate constant (Ka), 
Cl 
where K= (6) 
Vd 
7.2.4.1 Statistical model 
A log-normal distribution was assumed to describe the variability of the 
pharmacokinetic parameters. 
The error models for interindividual variability in the jth individual were :-
In CI
j = In true Cl. J + "CIj 
or CIj = true Cl. * J exp( rpj) ( 7 ) 
and similarly, 




Ka j = true Ka. * exp (n
Kaj ) 
J 
( 9 ) 
where n has a mean value equal to zero and a covariance matrix Q. 
Residual variability in the ith concentration of the jth individual was modelled as 
follows:-
Measured C;j = Predicted C;j * exp (E ij ) ( 1 0) 
where E has a mean value equal to zero and variance of a2. 
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The standard error (SE) of the parameters, Cl, Vd and Ka and the variances 
(SE
var
)' 0 2 and Q are estimated by NONMEM. The standard error of the inter- and 
intra-individual variability was approximated using equation (11), 
SE = (n or E + SE ) O. 5 - (n or E) O. 5 
var 
( 11 ) 
and expressed as a percentage (Vozeh et aI, 1982). 
The RKK data consisted of samples collected during the post-absorptive phase, as 
required for purposes of therapeutic drug monitoring. During the analysis of this 
data therefore, the values of Ka for TheodurR and Euphyllin RetardR were fixed at 
0.18 hr-1 and 0.462 hr-1 respectively as estimated from the prior analysis of the data 
from Study 1. 
7.2.4.2 NONMEM regression model 
Absorption rate constants (Ka) for all 3 preparations under study were obtained by 
use of the following regression model which was coded into the user-written 
subroutine PK of the PREDPP package using standard FORTRANR. 
( 1 2 ) 
where PREP = 1, 2, or 3 depending on whether the patient had received 
AlcophyllinR elixir, TheodurR tablets or Euphyllin RetardR tablets respectively. In 
this way, the values of 03' 05 and 06 in the PK subroutine could be constrained to 
equal zero where applicable in order to differentiate the Ka values for all three 
preparations. 
A second regression model was implemented in order to test the null hypothesis 
that smoking does not exert a significant influence on theophylline clearance. 
CL = (8, + (SM * 8 4 » * wt ( 1 3 ) 
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where Wt is the body mass in kg and the value of SM was either 1 or 0 depending on 
whether the patient was a smoker or non-smoker respectively. 
7.2.5 Criteria for hypothesis testing (Grevel et ai, 1988) 







Each NONMEM run provides in its output the value of its objective 
function, which is 2 times the negative logarithm of the likelihood 
function. The difference in the value of the objective function 
(DOBF) obtained for the general and the constrained model is 
approximately chi square distributed with degrees of freedom equal to 
the number of fixed parameters. A DOBF of more than 8 indicates a 
significant improvement (p < 0.005) in the fit of the data and suggests 
that the constrained model should be accepted. 
A minimum of correlation between parameters by inspection of the 
correlation matrix of the estimate provided in the NONMEM output. 
A value close to 1.0 is regarded as perfect correlation. 
Small standard errors of the estimates. 
Weighted residuals which are randomly scattered around zero when 
plotted against the predicted concentration. 
Decrease in the estimate of inter-individual variances. 
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7.3 RESULTS 
7.3.1 Hypothesis testing - see Table X 
Table X - HYPOTHESIS TESTING: 








( 96 ) 
function 
( 96 ) 
Matrix 
STUDY f 
Cl not influenced 
by smoking 0.0571 (0.0197) 42 (22) 712.642 20 (5) Cl vs Vd = 0.92 8 
(general model) 
Cl corrected 
for smoking 0 .0441 (0.0039) 32 (9) 766.135 20 (4 ) CL vs Vd = 0 .834 
(constrained model) 
STUDY 2 
Cl not influenced 
by smoking 0.0505 (0.0168) 50 (3) 209 .606 34 ( 12) Cl vs Vd = 0.896 
(general model) 
Cl corrected 
for smoking 0.0375 (0.004) 25 (4) 187.260 25 (3.9) Cl vs Vd = 0 .80 2 
(constrained model) 
standard error is shown in parenthesis 
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Study 1 
The objective function showed an increase from 712.642 (general model) to 766.13 
(constrained model) i.e. the DOBF of greater than 8 required for rejection of the 
null hypothesis at the p < 0.005 confidence interval was not observed. 
The correlation between the parameters, Cl and Vd decreased from 0.928 for the 
general model to 0.834 for the constrained model. 
The standard errors of both the fixed and the random effect parameters for the 
constrained model are smaller than that obtained with the general model. 
The graphs of weighted residuals against predicted concentrations are shown in Fig. 
10. The graph for the constrained model (Fig. 10.2) shows a more random scatter of 
data points around zero when compared with that of the general model (Fig. 10.1). 
The interindividual variability in Cl decreased from 42% to 32%. 
Study 2 
The value of the objective function decreased from 209.606 (general model) to 
187.260 (constrained model). This corresponds to a DOBF of 22. 
The value of the correlation matrix decreased from 0.896 for the general model to 
0.802 for the constrained model. 
The standard errors for the Cl parameter and the intraindividual variability 
displayed a decrease while the standard error for the interindividual variability 
showed a small increase (from 3% to 4%). 
The graphs of weighted residuals against predicted concentrations are shown in Fig. 
11. The graph for the constrained model (Fig. 11.2) shows a more random scatter of 
data points around zero when compared with the graph for the general model 
(Fig. 11.1). 
The estimate of the interindividual variability in Cl decreased from 50% to 25%. 
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Fig. 10 - Hypothesis testing - Criterion No. 7.2.5.4 - Study 1 
9 . 00E·00 
Graph of weighted residual (WRES) vs predicted serum theophylline concentration 
(PRED) for the general (10.1) and the constrained (10.2) regression models. Note 
the data points randomly scattered around zero in graph for the constrained model. 
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Fig. 11 - Hypothesis testing - Criterion No. 7.2.5.4 - Study 2 
Graph of weighted residual (WRES) vs predicted serum theophylline concentration 
(PRED) for the general (11.1) and the constrained (11.2) regression models. Note 
the data points randomly scattered around zero in graph for the constrained model. 
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7.3.2 Population pharmacokinetic parameters 
The fixed and random effects parameters for both studies are shown in Tables XI 
and XII. 
Table XI - FIXED EFFECTS PARAMETERS 
PARAMETER STUDY 1 
Clron~ ... 0.0441 (0.0039) 
(ilkg/hr) 






KaEl .. 4.61 (1.17) 
(hr·' ) 
Ka~",,,,,, ... 




All values quoted are the population mean with the 








Table XII - RANDOM EFFECTS PARAMETERS 
PARAMETER STUDY 1 i 
Interlndiv idual 
variability In Cl 32 (9) 
( %) 
Interindividual 
variability in Vd 61 (20) 
(%) 
Interindivldual 
variabil ity in Ka 107 (41) 
(%) 
Intraindivldual 
variability 20 (4) 
(%) 
All values reported are the population mean with the 










The study of population pharmacokinetics has its most important role in therapeutic 
drug monitoring programmes that utilise the Bayesian forecasting technique 
(Whiting et ai, 1986). Although the Bayesian feedback technique has been shown to 
be superior to all other currently available techniques for theophylline dosage 
design (Hurley and McNeil, 1988), a prerequisite for obtaining accurate results with 
this method is good initial estimates of both the pharmacokinetic parameters as well 
as their variances. The greater the confidence in these prior distributions, the better 
will be the performance of the associated Bayesian system. 
The distinction of the NONMEM method of population pharmacokinetic data 
analysis, is the ability to exploit routine clinical data. In this study, however, 
available data from a traditional pharmacokinetic study was also analysed. In 
addition to providing estimates of the average pharmacokinetic parameters of this 
population, this data facilitated the estimation of Ka values for TheodurR and 
Euphyllin RetardR which were subsequently used in the analysis of the RKK data. 
Since Ka values are formulation dependent parameters, it appears reasonable to 
assume that the values obtained in Study 1 would be relevant for the Study 2 
population. The purpose for which samples were collected in the RKK patients viz. 
theophylline dose individualisation, precluded the collection of samples during the 
absorptive phase. For purposes of dose individualisation samples collected during 
the absorptive phase are avoided due to the many factors affecting drug absorption 
(see Section 1.5.1). 
A review of the literature on theophylline's pharmacokinetics reveals that after oral 
administration, the drug distributes rapidly into tissues with the early distribution 
phase being complete within 30 - 45 minutes. It is for this reason that a one 
compartment model was chosen to analyse the data. Other authors have also found 
that pharmacokinetic analysis applied using this model gives satisfactory results 
(Loughnan et ai, 1976). 
NONMEM allows for different error structures to be used in the determination of 
inter- and intra-individual variability. In this study, the exponential error model was 
chosen i.e. the variability in the pharmacokinetic parameters was assumed to be 
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log-normal. It has been previously shown (Vozeh et ai, 1982; Maitre et ai, 1987 and 
Grevel et a11988) that a log-normal rather than a normal distribution describes the 
interindividual variability in pharmacokinetic parameters appropriately since the 
distributions of individual parameters in a patient population are generally skewed. 
When testing for the influence of smoking on theophylline clearance in Study 1, four 
of the five criteria for rejection of the null hypothesis were satisfied while in Study 2, 
all 5 criteria were fulfilled. The null hypothesis that smoking does not influence 
theophylline clearance was therefore rejected. In Study 1, the criterion not satisfied 
viz. DOBF (which displayed an increase instead of the required decrease of greater 
than 8) was until recently considered to be the most important one. If this had been 
regarded as the sole criterion in the present study then it would have been 
incorrectly concluded that smoking does not influence theophylline clearance. 
Indeed two recent reports (Mungall et ai, 1985; Maitre et ai, 1987), a workshop on 
NONMEM data analysis (Beal et ai, 1986), as well as numerous reports on 
NONMEM claim that DOBF is sufficient criterion to select the most appropriate 
model to describe the data. 
The observation in the present study that DOBF cannot be used as the sole 
criterion in accepting or rejecting a model is supported by similar observations by 
Grevel et ai, 1988. In their investigation of the population pharmacokinetics of 
metoclopramide using the NONMEM approach, they noted that particular 
demographic factors did not consistently cause changes in DOBF for all models. 
The populations used in the data analysis were a group of volunteers (Study 1) and a 
group of asthmatics (Study 2). In the ensuing discussion regarding the 
pharmacokinetic parameters estimated by NONMEM, comparisons are made with 
similar populations of volunteers or asthmatics (as indicated) whose 
pharmacokinetic parameters have been reported in the literature (Table 11, 
Chapter 1). 
The value of 0.0441 ± 0.0039 L/kg/hr for clearance in the group of non-smoking 
volunteers (VeT data) is very similar to a value of 0.0402 ± 0.0078 reported by 
Powell et al (1977) in a study of 15 healthy non-smoking volunteers aged 20 - 32 
years. The clearance of 0.0375 ± 0.004 L/kg/hr reported in Study 2 (RKK data -
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non-smoking asthmatics) is similar to a value of 0.039 ± 0.011 L/kg/hr reported by 
Hendeles et al (1978) in a similar population of otherwise healthy non-smoking 
asthmatics. 
The clearance for the smokers in Study 1 (PUCHE data) of 0.0641 ± 0.0176 L/kg/hr 
matches the value of 0.063 ± 0.019 L/kg/hr obtained by Powell et al (1977) in a 
group of 7 heavy smokers aged 22 - 31 years. The value of 0.0505 ± 0.009 L/kg/hr 
obtained in Study 2 (RKK data) is lower than this value by approximately 20%. The 
RKK study did not differentiate between light and heavy smokers and this may 
partly explain the difference. The clinical relevance of this difference is that this 
population may require more conservative initial doses of theophylline. 
It is noteworthy that the relatively sparse data used in Study 2 has produced results 
that are comparable with those obtained from traditional pharmacokinetic studies. 
This is a reflection on the usefulness of the NONMEM approach to 
pharmacokinetic data analysis. 
The interindividual variation in clearance of 32% obtained in Study 1 is high. This 
may be accounted for on the basis of a difference in theophylline clearance due to 
age. Age was not included in another regression model in view of the small sample 
numbers. 
The value of 0.8 L/kg for Vd in both Study 1 and 2 is somewhat higher than that 
obtained by other workers - 0.5 L/kg, range 0.3 - 0.7 (see Section 1.5.2). These 
different results are most likely due to the fact that this data set consisted entirely of 
information collected during steady state conditions. Such data contains little 
information about the volume parameter (Mungall et at, 1985; Whiting et at, 1986; 
Grevel et at, 1988). The data also consisted entirely of information obtained after 
oral administration. A possible decreased bioavailability may therefore also 
contribute to the large value for the Vd. It must be noted that the Vd reported by 
NONMEM is in fact Vd/F. 'F' is a bioavailability factor and is usually assumed to 
have a value of one. However, any value of F less than unity will increase the 
corresponding value of Vd. 
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The interindividual variability in Vd obtained in Study 1 is also very large (61%). 
This large variability indicates that there is not much confidence in the value of the 
parameter. In the Study 2 population, on the other hand, due to difficulty in 
estimating a value for interindividual variability in Vd, a very low value was 
obtained with a large standard error of the estimate (0.42). This indicates that the 
parameter has not been precisely estimated and the 95% confidence interval is an 
umealistic 0 - 1.64 L/kg. 
The Ka values estimated by NONMEM for Euphyllin RetardR (0.462 hr-i) and 
TheodurR (0.18 hr-i) correspond to values used in currently available Bayesian 
forecasting computer programmes (Kelman et ai, 1982; Lenert et ai, 1982). A very 
large interindividual variability in Ka (107 ± 41%) was estimated by NONMEM. 
Similarly, other studies have reported large interindividual variability in absorption 
rates (Pollack et ai, 1984; Rogers et ai, 1985) particularly with sustained release 
preparations. This has been related to host factors such as gastrointestinal transit 
time, posture, and presence of food which may affect the rate of theophylline 
absorption (Glynn-Bamhart, 1988). 
However, the large variability seen in this study is still surprising if one considers 
that in Study 1, factors known to affect the absorption rate would have been 
carefully controlled. A possible reason here may be the influence of a time lag for 
absorption. In a study to determine the population pharmacokinetics of mexiletine 
(Vozeh et ai, 1982), implementation of an absorption time lag parameter 
significantly reduced the interindividual variability in the Ka. In the Vozeh study a 
different version of NONMEM was used. The version of NONMEM used in the 
present study does not have an appropriate means of determining lag time. 
This study has revealed that the pharmacokinetics of theophylline in members of the 
Indian population group shows close similarity with that reported on other 
population groups. An important outcome is the good agreement between the 
results of previous, more traditional forms of data analysis and those provided by 
this new methodology. This study has also facilitated quantification of the 
interindividual variability in theophylline pharmacokinetics. A knowledge of the 
fixed effect parameters are sufficient to guide initial dosage but in a particular 
patient the concentration actually achieved may differ considerably from the 
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expected average value. A knowledge of the inter-individual variability may enable 
one to place a level of confidence on the predicted concentration. This is achieved 
by calculating the 68% (Le. mean ± 1 SD) or the 95% (Le. mean ± 2 SD) confidence 
intervals. Such calculations may be done by means of currently available Bayesian 
forecasting computer programs such as OPTR • 
7.5 CONCLUSIONS 
1. NONMEM analysis of data from a population of smokers and non-smokers 
has confirmed that smoking has a significant influence on theophylline 
clearance. 
2. Analysis of routine clinical data on theophylline derived from non-smoking 
asthmatics, has yielded pharmacokinetic parameters for the Indian 
population that are in general agreement with published values in other 
population groups. 
3. However, theophylline clearance in asthmatic Indian smokers is 20% lower 
than that reported in smokers from other population groups. This suggests 
that a more conservative initial dose be used in these patients. 
4. The volume of distribution of 0.8 Ljkg is higher than that reported by other 
workers. In view of the reservations expressed regarding this value, it is 
recommended that a study designed to provide maximum information about 
this parameter be undertaken. 
5. Interindividual variability in theophylline clearance for the Indian population 
has been quantified. This enables greater confidence to be given to 
theophylline dosage design in this population group. 
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Theophylline, a dimethylated xanthine, is a popular bronchodilator drug and has 
been in use for many years, yet its mechanism of action is still elusive. The drug's 
beneficial effects relates primarily to actions on the respiratory system. These 
effects, as well as toxicity, correlate well with serum theophylline concentrations. 
Studies of theophylline pharmacokinetics reveals a wide interindividual variation in 
clearance, primarily because hepatic biotransformation is the major route of 
elimination. Numerous factors that affect theophylline clearance have been 
identified and are discussed in this chapter. 
Chapter Two 
Therapeutic drug monitoring is an expanding new discipline that uses drug 
concentrations in body fluids to optimise drug therapy. Recent interest in the field is 
in large part due to the availability of sensitive, specific and easy-to-use methods of 
drug and metabolite analysis. Theophylline concentration analysis is performed on 
blood, serum or plasma - saliva concentrations having been found to be unreliable. 
For accurate dosage predictions, appropriate timing of blood samples and 
interpretation of the drug concentrations are important considerations. The 
Bayesian technique of serum drug concentration interpretation is currently the most 
efficient and popular method available. 
Chapter Three 
Population pharmacokinetics attempts to find typical relationships between 
physiology, pathology and pharmacokinetics. An important application of 
population pharmacokinetics has been in therapeutic drug monitoring programmes 
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in order to improve dosage predictions. The NONMEM approach to population 
pharmacokinetic data analysis involves the use of data gathered directly from 
patients receiving the drugs of interest. Such an approach has definite advantages 
over more traditional methods that utilise volunteers or patients with lesser degrees 
of illness. 
Chapter Four 
The SeralyserR, an instrument for theophylline concentration analysis, has recently 
been introduced locally. Its performance was evaluated against the TDxR method 
using 52 serum samples collected from 34 asthmatics attending the Asthma Clinic 
at R K Khan Hospital. The linear regression equation for the line of best fit for 
SeralyserR (y) and TDxR (x) was y = 1.057x + 0.078 (r2 = 95.68%). The average 
cost per sample during the evaluation period was R15-47 for the SeralyserR and 
R13-59 for the TDxR. It is concluded that the SeralyserR,s performance compares 
favourably and without bias with the more established TDxR method. 
Chapter Five 
The influence of a therapeutic drug monitoring (TDM) programme on theophylline 
utilisation was evaluated over a 2 year period at R K Khan Hospital. Eighty seven 
asthmatics presenting to the Asthma Clinic were categorised as being controlled, 
toxic, non-compliant or uncontrolled based on serum theophylline concentration 
(STC) deterrninations and clinical assessments. A linear regression of dose on STC 
confirms the absence of any correlation between these parameters (r2 = 6.46%). 
Twenty one patients (24%) were found to be clinically controlled on their initial 
dose of theophylline. Twenty seven patients (31%) were categorised as being 
clinically toxic or to have STC's > 20 }.lg/ml while 24 patients (28%) were found to 
be non-compliant. Forty patients (46%) were considered to be clinically 
uncontrolled but 5 of these were excluded from further dosage adjustments because 
of fears of toxicity (STC's > 15 }.lg/ml). In the remaining 35 patients, dosage 
adjustment based on pharmacokinetic principles resulted in clinical improvement in 
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24 (68.6%) patients. This was statistically significant for the group (sign test 
p < 0.00001). These results illustrate the value of TDM in theophylline dosage 
design. 
Chapter Six 
Thirty five acute asthmatics were randomly included in a study to determine the 
consequences of administering a standard fixed dose of 250 mg intravenous 
aminophylline to all patients i.e. irrespective of body mass or history of prior intake 
of theophylline-containing preparations. Serum theophylline concentrations were 
determined 30 minutes after completion of a 2 hour infusion of the aminophylline 
dose. The results obtained indicate 40% of patients with levels < 10 }.lg/ml, 43% 
within the therapeutic range and 17% with levels> 20 }.lg/ml. Implementation of an 
alternate recommended dosage regimen based on body mass and history of prior 
intake of theophylline (5 mg/kg if no theophylline taken - otherwise 2.5 mg/kg) 
would have produced more acceptable results viz. 33% with levels < 10 }.lg/ml, 61 % 
within the range and 6% with levels> 20 }.lg/ml. 
Chapter Seven 
The pharmacokinetics of theophylline were determined in smokers and 
non-smokers using the NONMEM computer programme. Data from a traditional 
pharmacoRinetic study (23 subjects - approximately 15 samples per subject for each 
of 3 preparations under investigation) was used in order to determine absorption 
rate constants (Ka) for TheodurR and Euphyllin RetardR. These Ka values were 
subsequently used in the determination of theophylline's pharmacokinetics in the 
Indian asthmatic population attending R K Khan Hospital from whom routine 
clinical data was available (approximately two samples per patient in each of 30 
patients). The results obtained confirms that smoking has a significant influence on 
theophylline clearance. The pharmacokinetic parameters obtained for the 
non-smoking Indian asthmatic population from R K Khan Hospital are in general 
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agreement with published values of other population groups. However, theophylline 
clearance in Indian asthmatics who smoke was found to be approximately 20% 
lower than that reported in smokers from other population groups. This suggests 




Serum theophylline concentrations (J.tg/ml) measured 
using the SeralyserR and TDxR 
see Chapter Four 
SeralyserR TDxR SeralyserR TDxR 
4.7 4.17 6.9 5.67 
19.8 14.05 5.2 3.85 
6.1 5.27 21.2 18.65 
12.3 11.98 10.9 10.94 
6.1 5.62 17.9 16.43 
17.6 15.24 4.2 5.08 
20.3 19.3 4.5 5.88 
9.5 10.89 9.4 8.58 
17.3 15.27 17.3 15.52 
5.8 5.13 34.5 30.89 
14.8 14.73 10.3 10.23 
11.7 9.12 17 17.36 
16.4 13.31 9.2 9.2 
3.1 1.25 10.2 10.84 
7.6 6.28 21.3 19.97 
9.4 9.16 11.7 12.17 
6.5 3.97 11.8 13.15 
21.4 21.4 9.6 9.47 
14.6 14.38 <3 1.5 
3.7 3.37 <3 0.5 
25.3 25.49 <3 0.24 
5.5 5.77 <3 1.6 
10.1 10.07 <3 4.63 
7.3 8.56 <3 1.48 
5.6 6.11 <3 0.78 

















Group 1 - Patients stable on initial dose 
see Chapter Five 
Age Mass Dose Cp 
(yrs) 
Sex 
(kg) (mg/kg/day) (ug/m!) 
30 M 66.0 9.10 11.26 
39 M 58.0 10.30 10.90 
41 F 52.0 9.90 13.80 
35 F 75.0 6.80 7.32 
38 F 45.0 13.30 11.32 
60 F 81.0 7.40 12.05 
24 F 50.7 7.90 12.45 
25 F 57.5 8.90 12.39 
39 F 43.6 11.70 3.95 
51 M 61.0 9.80 10.38 
47 F 45.0 4.44 10.85 


























Table 81 (continued) 
Group 1 - Patients stable on initial dose 
see Chapter Five 
Age Mass Dose Cp 
(yrs) 
Sex 
(kg) (mg/kg/day) (ug/ml) 
57 F 61.7 8.30 7.42 
34 M 46.0 13.04 7.80 
46 F 64.0 9.40 15.00 
54 M 50.0 10.24 15.01 
37 F 69.0 8.70 19.10 
52 F 60.0 6.67 10.20 
45 F 48.0 10.67 10.90 
28 M 60.0 10.00 9.13 




















Group 2.1 - Patients NOT controlled on 
initial dose - Cp > or = 15 ug/ml 
see Chapter Five 
Age 
Sex 
Mass Dose Cp 
(yrs) (kg) (mg/kg/day) (ug/ml) 
37 F 61.0 9.84 15.50 
61 F 69.0 8.70 15.00 
23 F 88.3 5.80 17.35 
74 F 32.0 16.00 18.60 













106 25 F 
113 44 F 
130 37 F 
143 42 F 
144 23 M 
145 21 F 
150 27 M 
151 32 F 
152 43 M 
158 31 M 
160 31 F 
164 31 F 
Table 83 
Group 2.2 - Patients NOT controlled on 
initial dose - Cp < 15 ug/ml 
see Chapter Five 
Emergency room Hospital Dose Cp 
Mass 
visits Admissions (mg/kg/day) (ug/ml) 
(kg) 
Before/ After Before/After Before/After Before/After 
49.0 0.33/0 0.17/0 10.45/10.45 0/13.4 
67.0 1.5/0.2 0/0 7.65/8.96 6.7 /10.2 
64.0 0.83/0.33 0.33/0 8.0/9.38 10.42/14.60 
66.0 2/0 0.33/0 7.76/12.12 6.80/ 8.70 
48.0 0.5/0.75 0/0 12.5/16.67 7.79/ 10.40 
63.0 8/9 111 8.13/9.52 9.50/ 13.25 
48.0 12/3 1/0.67 10.67/18.75 5.60 / 9.90 
60.5 1/0 0/0 6.61/9.92 3.8017.40 
68.0 Frequent Frequent 8.82/11.76 13/16 
56.0 1.75/0 0/0 9.15/12.50 12.51 / 17.10 
76.5 0/ 0 0/ 0 5.2317.84 10.14/ 14.20 
67.5 Frequent Frequent 7.58/ 11.85 6.14/ 9.59 
Emergency room visits and hospital admissions are average over 
3 to 6 months. 
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Comments 
now on steroids 
not improved 
not improved 
now on steroids 
not improved 
now on stero ids 
not improved 
Age 
Id (yrs) Sex 
165 51 M 
171 37 F 
177 48 F 
182 32 F 
187 27 F 
193 24 F 
199 55 M 
205 36 M 
210 47 M 
234 47 M 
235 55 F 
247 15 M 
Table 83 (continued) 
Group 2.2 - Patients NOT controlled on 
initial dose - Cp < 15 ug/ml 
see Chapter Five 
Dose Emergency room Hospital Cp 
Mass 
visits Admissions (mg/kg/day) (ug/ml) 
(kg) 
Beforel After Beforel After Beforel After Beforel After 
56.0 Frequent Frequent 9.14/10.71 9.16/10.73 
65.0 0/0 0/0 7.88/11.82 7.43/11.14 
60.0 0/0 0/0 8.50/10.0 12.13/14.22 
65.0 1.5/0 0/0 7.88/9.23 10.01/14.70 
62.0 3/4 0/1 8.26/9.68 10.75/14.7 
55.6 110 0/0 6.4717.19 0/14.28 
57.0 0.67/1.67 0/0 8.98/10.53 14.97117.54 
65.1 4.25/2.38 0.67/0 9.20/12.27 13.2/17.6 
64.1 1/0.33 1/0 7.99/9.36 11.46/13.42 
50.0 5.1712 0/0 10.24/12.0 15.24/17.86 
70.0 0/0 0/0 4.29/5.71 4.86/6.49 
41.0 Frequent Frequent 12.5/14.63 6.9/11 .3 
Emergency room visits and hospital admissions are average over 











249 45 M 
253 48 F 
254 29 M 
255 13 M 
257 42 M 
265 50 F 
266 44 M 
286 34 M 
287 29 M 
292 34 M 
299 13 F 
Table 83 (continued) 
Group 2.2 - Patients NOT controlled on 
initial dose - Cp < 1Sug/ml 
see Chapter Five 
Emergency room Hospital Dose Cp 
Mass 
visits Admissions (mg/kg/day) (ug/ml) 
(kg) 
Beforel After Beforel After Before/After Beforel After 
43.0 Frequent Frequent 11.91/20.93 6.61/11.63 
50.0 5/5 112 10.84/12.00 10.67/12.50 
50.0 1.33/0.25 0.33/0 10.24/16.00 8.89/13.89 
34.0 1.00/0.33 0.33/0 8.82/17.65 5.70/11.40 
57.0 2.30/0 0.33/0 8.99/8.77 0/12.18 
75.6 1.50/0 0.25/0 6.7817.94 10.46/12.25 
50.0 9/9 0/0 12/14 13.64/15.91 
47.0 1.2/0.4 0/0 12.77117.02 5.80/8.06 
49.0 1/0 0/0 10.45/12.25 8.42/9.87 
48.0 0/0 0/0 10.67116.67 7.89/12.32 
44.5 1.33/0 0.67/0 4.49/8.98 5.70/10.60 
Emergency room visits and hospital admissions are average over 












102 68 M 58 
107 68 M 55.0 
125 68 F 78.0 
125 68 F 78.0 
129 61 F 92.0 
131 65 F 67.0 
136 66 M 62.2 
138 48 M 75.8 
140 12 M 27.5 
152 43 M 68.0 
159 36 F 69.5 
159 36 F 69.5 
191 47 M 56.2 
Table B4 
Group 3 - Patients clinically toxic 
or Cp > 20 ug/ml 
see Chapter Five 
Dose Cp 
Route Symptoms 
(mg/kg/ day) (ug/m!) 
17.30 23.80 ivl nausea,tremor,irritable 
9.30 22.25 p.o. tachycardia 
5.13 21.05 p.o. none 
7.7 20.20 p.o. seizure 
6.52 18.60 p.o. nausea,tachycardia 
5.97 26.05 p.o. nausea,vomitting,tremor 
9.65 17.36 p.o. none 
11 .87 25.49 p.o. nausea ,seiz ure 
14.50 23.00 p.o. nausea ,irritable,headache 
8.82 17.75 p.o. insomnia 
14.73 21.40 p.o. tremor 
? 34.50 ivi + p.o. irritable, tremor 






6 months after above 
CHF 
average Cp=23.8 ug/m l 
CHF 
CHF 




average Cp=27 .6 ug/ml 
over compliance 






191 47 M 56.2 
194 70 F 35.0 
199 55 M 57.0 
219 36 F 54.0 
246 71 F 46.5 
246 71 F 46.5 
247 15 M 41 .0 
247 15 M 41.0 
250 54 M 50.0 
251 32 F 43 .0 
262 46 F 45.0 
267 48 M 46.5 
284 53 F 50.8 
285 29 F 36.9 
Table 84 (continued) 
Group 3 - Patients clinically toxic 
or Cp > 20 ug/ml 




10.68 24.65 po none 
17.14 25.25 po tachycardia, t remor 
10.53 18.05 po nausea 
11 .01 30.89 po none 
12.9 38.30 po vomitting, nausea 
12.9 23.05 po vomitting, nausea 
? 42.00 Ivi + po Irritable 
? 21 .90 ivi + po tachycardia 
15.36 29.80 po none 
? 22.45 po none 
? 16.50 ivi + po seizure 
? 24.35 Ivi + po tremor 
11 .81 34.65 po none 





average Gp = 20.6 ug/ml 
GHF 





Euphyllin + Franol 
estimated Gp at time of 





Id (yrs) Sex (kg) 
106 25 F 49.0 
127 28 F 41.0 
138 48 M 75.8 
145 21 F 63.0 
146 21 F 53.5 
150 27 M 48 
151 32 F 60.5 
159 36 F 69.5 
180 28 M 58.0 
185 54 M 57.0 
209 15 M 43.0 
214 17 M 60.0 
Table 85 
Group 4 - Patients with compliance 
problems 
see Chapter Five 
Dose Nature of non Detected at 
Corrected 
(mg/kg/day) compliance Interview 
10.45 UNDERDOSING NO YES 
12.49 BOTH YES NO 
7.92 OVERDOSING YES YES 
8.13 OVERDOSING YES NO 
11.22 UNDERDOSING NO YES 
18.75 UNDERDOSING YES NO 
9.92 UNDERDOSING NO YES 
7.37 OVERDOSING YES YES 
13.79 OVERDOSING YES NO 
8.98 UNDERDOSING NO YES 
11.63 UNDERDOSING NO YES 



















230 45 F 56.0 
247 15 M 41.0 
249 45 M 43.0 
255 13 M 34.0 
257 42 M 57.0 
260 44 M 55.0 
265 50 F 75.6 
266 44 M 50.0 
267 48 M 46.5 
269 56 F 66.4 
287 29 M 49.0 
299 13 F 44.5 
Table 85 (continued) 
Group 4 - Patients with compliance 
problems 
see Chapter Five 
Dose Nature of non Detected at 
Corrected 
(mg/kg/day) compliance interview 
9.14 UNDER DOSING NO NO 
14.63 UNDERDOSING NO NO 
11.91 UNDERDOSING YES YES 
8.82 UNDER DOSING NO YES 
8.98 UNDERDOSING NO YES 
10.91 UNDER DOSING YES YES 
7.94 UNDERDOSING NO YES 
14.00 UNDERDOSING YES NO 
11.01 UNDERDOSING YES YES 
9.04 UNDERDOSING NO YES 
12.25 UNDERDOSING NO YES 

















Patients treated with aminophylline at the emergency room 
Serum theophylline concentrations < 10 ug/ml 
see Chapter Six 
Age Mass Dose src Use in prior Expected src with HWJ dose Id Sex 
(yrs) (kg) (mg/kg) (ug/ml) 12 - 24 hours (ug/ml) 
116 M 64 44 4.86 8.75 Y 4.81 
119 M 16 44 4.86 9.15 Y 5.03 
139 M 30 57 3.75 5.85 N 8.33 
164 F 31 73 2.93 6.93 N 11.79 
169 F 48 63 3.40 7.6 N 11.99 
187 F 27 62 3.45 9.2 Y 7.12 
205 M 36 65.2 3.28 6.9 Y 5.62 
208 F 43 65 3.29 9.45 N 15.34 
217 F 44 55 3.89 9 N 12.36 
221 M 31 53 4.04 8.5 Y 5.64 
221 M 31 53 4.04 6.5 N 8.62 
254 M 29 50 4.28 8.1 Y 5.06 
267 M 48 46.5 4.60 9.16 N 10.65 





Patients treated with aminophylline at the emergency room 
Serum theophylline concentrations between 10 - 20 ug/ml 
see Chapter Six 
Age Mass Dose STC Use in prior 
Expected STC 
with HWJ dose Id Sex 
(yrs) (kg) (mg/kg) (ug/ml) 12 -24 hours (ug/ml) 
118 M 30 62 6.90 15.45 N 11.99 
145 F 21 63 3.40 18.7 Y 17.34 
157 M 65 69 3.10 13.3 Y 12.52 
158 M 31 56 3.82 14.6 Y 12.46 
164 F 31 68 3.15 17.6 Y 16.68 
164 F 31 73 2.93 12.6 Y 11.72 
170 M 31 43 4.98 10.5 Y 6.2 
180 M 28 56 3.82 11.3 Y 9.16 
180 M 28 56 3.82 13.9 Y 11.76 
187 F 27 62 3.45 14.9 Y 13.44 
195 F 50 89 2.40 19.2 Y 19.7 
253 F 48 53 4.04 16.4 Y 13.86 
254 M 29 50 4.28 17.2 Y 14.2 
329 M 28 58 7.38 16 N 11.59 
333 M 47 61 7.02 10.7 N 8.16 
153 
Table C3 
Patients with aminophylline at the emergency room 
Serum theophylline concentrations > 20 ug/ml 
see Chapter Six 
Age Mass Dose STC Use in prior 
Id Sex 
(yrs) (kg) (mg/kg) (ug/ml) 12 - 24 hours 
148 M 39 61 3.51 20.3 Y 
187 F 27 62 3.45 21.2 Y 
199 M 55 57 7.51 26.75 Y 
267 M 48 46.5 4.60 24.35 Y 
288 F 40 62.5 3.42 31.6 Y 
320 M 38.5 58 3.69 22 Y 
154 
Expected STC 











NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 1 
Male, 88kg, 60yr, 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (}.lg/ml) (hr) (llg/ml) 
0 1 .7 0 4.5 0 6.8 
0.25 3. 1 0.5 5. 1 0.5 7.2 
0.48 4.2 1. 02 6.1 1 6.9 
0.75 4. 1 2 7.2 2 7.3 
1 4.6 2.98 6.9 3.07 8.6 
1. 48 4.2 4 6.7 4 6.3 
1 .97 4.3 6.12 6.1 5.93 6.7 
2.47 5.2 8 6.2 8 6. 1 
3 3.9 12.05 3.7 11. 93 4.3 
4.02 3.6 24. 1 0.7 23.7 1 .3 
5.98 2.5 27.07 0.5 26.38 0.8 
7.92 1 .6 33 0.2 32.43 0.42 
11. 88 0.75 
23.9 0.1 
26.95 0.07 
Subject No. 2 
Male, 70.5kg, 45yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (}.lg/ml) (hr) (}.lg/ml) 
0 2.3 0 4.9 0 4.2 
0.22 5.9 0.53 4.6 0.47 3.5 
0.48 7.1 1 6.2 0.98 3.4 
0.73 5.9 1 .98 6 2.02 3.4 
1 5.9 2.98 4.4 3.03 3.2 
1 .5 5.2 3.98 3.3 4.03 3.1 
2 5.4 6.03 0.5 6.03 3.5 
2.63 4.8 8.02 0.9 7.95 4 
3. 17 4.9 11 .87 1.0 11 .02 4.1 
4. 13 4.2 23.37 0.5 11 .75 2.7 
6.17 3.1 26.38 0.28 26.78 0.75 






NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 3 
Female, 48kg, 
41yr, Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (l1g/ml ) (hr) (l1g/ ml ) (hr) (l1g/ ml ) 
0 5.5 0 8.5 0 10.3 
0.25 13.9 0.48 8.3 0.48 11 .8 
0.50 14.7 1 .12 8.1 1 13.9 
0.75 15.7 2.08 7.9 1 .98 13.3 
1. 03 14.8 3.08 8.6 2.98 13.3 
1 .70 12.9 4. 12 7.7 3.98 12.4 
2.00 12.8 6.07 7.8 6.07 12.8 
2.55 10. 1 8. 1 7.4 7.8 13.9 
3.08 10.7 12.02 6.2 12.02 10.6 
4.08 10.3 23.62 1.6 23 . 78 3.2 
6.05 9. 1 26.88 1 .2 26.97 2 
8.00 5.0 32.8 0.58 32.73 0.97 
11. 92 5.1 
23.53 1 .00 
26.5 0.76 
Subject No. 5 
Male, 72.3kg, 28yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (l1g/ml ) (hr) (l1g/ ml ) (hr) (l1g/ml ) 
0 2.4 0 6. 1 0 5.7 
0.25 9 0.5 6.8 0.5 5.3 
0.48 6.4 1 7 1 5.9 
0.75 6.3 2 6.8 2.05 6.4 
1 5.7 2.93 6.2 2.98 6.6 
1 .48 5.7 3.92 6 4.13 6.7 
2 4.9 5.92 5.6 5.92 7.3 
2.48 4.9 7.92 4.6 8.05 7.7 
2.98 4.5 11. 93 4.6 11 .83 5.4 
4.02 4.3 23.62 1 .5 23.65 1 . 1 
5.98 3.2 26.82 1.2 26.75 0.8 
8 2.3 32.92 0.9 32.82 0.4 






NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 6 
Male, 85.2kg, 
30yr, Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 2.1 0 2.7 0 3.7 
0.22 6.4 0.5 3.1 0.63 6.5 
0.48 6.2 1 3.3 1 6.9 
0.73 5.4 2.05 5.2 2.02 8.6 
0.98 5.0 2.98 6.6 3 9.5 
1 .48 4. 1 4 8.2 4 10.2 
1 .97 3.7 6.08 6. 1 6 10. 1 
2.52 3.4 7.95 4.3 7.93 7.8 
2.98 2.9 11. 95 3.3 11 .8 6. 1 
3.97 2.6 23.92 1 .6 23.7 1 . 1 
5.92 2. 1 27 3.4 26.65 0.5 
7.92 1 .4 32.78 0.4 32.75 0.4 
11 .87 0.8 
23.9 O. 13 
26.98 0.1 
Subject No. 7 
Male, 71.5kg, 45yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 0.2 0 2.1 0 1 .9 
0.25 4.9 0.5 3 0.48 2.8 
0.50 3.8 1 .02 2.8 0.98 2.8 
0.73 4 2 4.1 2.03 2.9 
1 3.3 2.77 3.2 3 3 
1 .52 3.8 4. 18 2.8 4.08 2.3 
2. 1 2.4 6.05 2.6 6.03 1 .9 
2.43 2.3 8.07 2.3 8.03 2.8 
2.85 2.2 11 .9 1 .4 11 .97 2.4 
3.93 1 .8 23.98 0.4 23.72 0.3 
6.02 1 .0 27 0.2 
8.07 0.7 33.05 0.01 
11 .93 0.3 
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Table D4 
NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 8 
Male, 82.2kg, 
33yr, Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (l-lg/ml) (hr) (l-lg/ml) (hr) (l-lg/ml) 
0 3.4 0 2.7 0 8.2 
0.25 4.9 0.5 2.9 0.48 8 
0.5 6. 1 0.98 4.4 1 8.9 
0.75 6.6 1 .95 5.3 2 8.7 
1 6.4 2.9 4 3 9.2 
1. 52 6.4 3.92 4.8 3.98 9.8 
2 6.7 5.98 4 6.02 10.3 
2.5 5.8 7.92 3.9 7.92 9.7 
3 5.1 12.08 3.8 12 7.2 
4 5.9 23.97 1.1 23.98 1 .6 
6 4.7 26.98 0.7 26 . 95 1 .2 
7.9 3.7 32.93 0.4 32.82 0.7 
11 .8 2.4 
23.38 0.5 
32.8 0.18 
Subject No. 9 
Female, 58kg, 44yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (l-lg/ml) (hr) (l-lg/ml) (hr) (l-lg/ml) 
0 0.6 0 3. 1 0 5.7 
0.23 2.9 0.5 3.2 0.5 6.7 
0.48 4.7 1 .02 3.4 1 6.8 
0.73 5.2 2.03 3.6 1 .95 7.1 
0.98 4.4 3.2 3.3 2.97 7 
1.5 4.3 4. 12 2.8 4.03 7.3 
2.02 4.3 6.12 2.6 6 6.3 
2.53 3.7 7.95 1 .4 8 5.1 
3.03 3.7 11. 95 0.4 11. 95 2.5 
4.13 1.5 23.92 O. 1 23.7 0.6 
6.12 1 . 1 26 . 83 0 . 2 26.93 0.4 




NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 10 
Female, 58.5kg, 
40yr, Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (ug/ml) (hr) (ug/ml) (hr) (ug/ml) 
0 2 0 6.4 0 6.1 
0.25 3.5 0.5 7.3 0.48 7 
0.48 4.5 1 8.8 0.98 7.1 
0.77 5.6 2.02 8.3 2.02 7.8 
1 .02 4.8 3 8.9 3 7 
1 .5 6.3 4 9.1 4. 1 5 
2 6. 1 6 7.3 6.07 7.3 
2.50 6.3 8 6.6 8. 1 6.3 
3 5.9 12.35 3.8 12. 13 6.6 
4.02 5.4 23.75 3.8 23.72 1.2 
6.02 3.7 27 2.7 26.92 0.7 
7.93 2.6 32.77 1 .3 32.77 0.3 
12. 1 1 .4 
24.08 0.2 
28.17 0.08 
Subject No. 1 1 
Male, 71.2kg, 24yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (ug/ml) (hr) (ug/ml) (hr) (ug/ml) 
0 1 0 2.4 0 6.4 
0.25 2.3 0.48 2.4 0.52 6.4 
0.5 4. 1 1 3.2 1 6 
0.73 4.2 2 4.4 2 6 
1 3. 1 2.98 6. 1 3.02 6.4 
1 .3 3.5 3.93 5.7 4 5.7 
2.02 3.3 5.79 5.7 5.92 5.7 
2.52 3.5 7.69 5.3 8. 17 4.7 
3 3.1 12.03 1 . 7 12. 1 4.8 
3.92 3.2 23.9 0.7 24.12 1 .7 
5.88 2 27.02 0.6 26.2 1.4 
7.83 1.6 33.02 0.3 29.12 1 . 1 
11 .92 0.8 




NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 12 
Male, 78kg, 22yr, 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 2.6 0 4.8 0 5.8 
0.27 3.6 0.47 5.2 0.5 6.3 
0.5 6.2 0.98 5.3 1 .5 6.7 
0.75 5.3 2.02 4.9 2.5 5.4 
1. 02 5.9 2.97 4.4 3.5 5.7 
1. 48 5.7 3.98 4.2 4.5 5.8 
1.98 5.6 5.95 3.6 6.48 4.1 
2.48 5 7.93 3.1 8.48 4. 1 
3 5 12 2.5 12 4.3 
4 4.9 23.8 2 23.43 1.9 
5.98 3.6 26.9 2.6 26.43 1 .7 




Subject No. 13 
Male, 97.5kg, 25yr 
Smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 1 0 1 .3 0 3.9 
0.23 1.3 0.5 1 .5 0.52 4.1 
0.48 3.6 1 1.8 0.98 4.3 
0.73 4 2 1 .9 2 4.4 
0.98 3.8 2.98 2.4 3.03 4.4 
1 .45 3.5 4 1 . 7 4 4.3 
2 3.4 6 1 .6 5.88 3.5 
2.48 3.2 8 1.2 8.23 3.7 
2.97 3.1 12. 1 1 .0 12. 13 3. 1 
4 2.4 24.53 1.4 24.15 0.6 
5.18 2 26.15 1 . 1 26.68 0.5 






NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 14 
Male, 73kg, 20yr, 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (V-g/ml ) (hr) (V-g/ ml ) (hr) (V-g/ml ) 
0 4.3 0 4 0 7 
1 6.1 1 5.1 1 7 . 1 
2 7.8 2 4.7 2 6.2 
3 8 3 4.6 3 6. 1 
4 7 . 1 4 4.2 4 5.9 
6 5.6 6 6 6 7 
8 5.3 8 6.5 8 10.4 
12 2.9 12 5.5 12 8.2 
24 1 .6 24 1 .9 24 2.4 
27 1 .2 27 1 .9 
33 0.6 33 1.1 
Subject No. 15 
Male, 1 05kg, 20yr 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (V-g/ml ) (hr) (V-g/ ml ) (hr) (v-g/ml) 
0 3 0 3.0 0 6.4 
1 5.5 1 3.3 1 6.6 
2 6. 1 2 3.3 2 7.2 
3 5.5 3 8.6 3 6.7 
4 5.4 4 6.2 4 6.7 
6 4.2 6 6. 1 6 9.2 
8 3.9 8 5.0 8 8.6 
12 2.6 12 3.6 12 6.4 
24 0.6 24 0.8 24 2.1 




NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 16 
Male, 81kg, 20yr, 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 2.6 0 4 0 7 
1 4.6 1 3.8 1 7.5 
2 5.7 2 4.1 2 7.5 
3 5.6 3 3.5 3 7.5 
4 5.9 4 3.8 4 7.1 
6 4.9 6 2.2 6 8.6 
8 3.7 8 2.4 8 7.9 
12 2.4 12 1 .9 12 5.9 
24 0.9 24 0.8 24 1 . 7 
33 o . 1 27 1 .6 
33 0.8 
Subject No. 17 
Male, 70kg, 20yr 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (JJ.g/ml) (hr) (llg/ml) 
0 3. 1 0 7.3 0 7.5 
1 5.1 1 5.2 1 6.9 
2 5.8 2 7.3 2 6.3 
3 6.0 3 6.5 3 5.5 
4 5.0 4 6. 1 4 5.9 
6 4.3 6 9.5 6 7.6 
8 3.5 8 10.2 8 8.7 
12 3.0 12 8.6 12 7.6 
24 0.9 24 3.4 24 2.8 
27 3.0 27 2.5 
33 1 .7 33 1 .3 
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Table D9 
NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 18 
Male, 69.6kg, 
20yr, Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (J.1g/ml) (hr) (J.1g/ml) (hr) (J.1g/ml) 
0 2.9 0 3.0 0 5.5 
1 5 1 3.3 1 4.7 
2 5.8 2 3.3 2 5. 1 
3 6 3 3.8 3 4.8 
4 5.3 4 6. 1 4 4.3 
6 4.1 6 6.4 6 5.7 
8 3.6 8 5.7 8 5.5 
12 2.3 12 4. 1 12 4.4 
24 0.7 24 1.4 24 0.9 
27 1.0 27 0.6 
33 0.4 33 0.1 
Subject No. 19 
Male, 76kg, 20yr 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (J.1g/ml) (hr) (}.lg/ml) (hr) (}.lg/ml) 
0 1 .3 0 4.2 0 5.7 
1 3.5 1 3.8 1 4.7 
2 3.9 2 3.7 2 5. 1 
3 3.5 3 3.3 3 4.6 
4 3.3 4 3.3 4 4. 1 
6 2.6 6 3 6 4.0 
8 1.9 8 2.8 8 4.1 
12 1 . 1 12 3.5 12 6.7 
24 0.5 24 2.3 24 1 . 7 
27 1.8 27 1 .3 
33 0.3 33 0.4 
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Table DIO 
NONMEM Data Set - Study 1 
see Chapter Seven 
Subject No. 20 
Male, 76.9kg, 
20yr, Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) ()..Lg/ml) (hr) ()..Lg/ml) (hr) ()..Lg/ml) 
0 4.2 0 5.9 0 8.2 
1 7 . 1 1 5.9 1 7.7 
2 8.3 2 5.4 2 7.7 
3 7.9 3 5.4 3 8.3 
4 7.6 4 5.7 4 7.2 
6 6.3 6 7.7 6 9.2 
8 5.8 8 ' 7. 1 8 10.4 
12 3.8 12 6.9 12 9.0 
24 1 .7 24 3.0 24 3.5 
27 2.6 27 3.5 
33 1.6 33 2.2 
Subject No. 21 
Male, 75.5kg, 20yr 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) ()..Lg/ml) (hr) ()..Lg/ml) (hr) ()..Lg/ml) 
0 4.9 0 2.8 0 9.2 
1 8.3 1 2.4 1 10.0 
2 10.0 2 3.2 2 9.0 
3 9.7 3 4.3 3 8.7 
4 10.0 4 4.2 4 6.5 
6 8.3 6 6.9 6 7.9 
8 6. 1 8 6.3 8 7.3 
12 4.7 12 5.6 12 8.3 
24 1 .7 24 2. 1 24 4.1 
27 2.0 27 4.1 
33 1 .2 33 2.3 
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Table DII 
NONMEM Data Set - Study I 
see Chapter Seven 
Subject No. 22 
Male, 69.5kg, 
20yr, Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 4.7 0 6.8 0 9.0 
1 6.2 1 9.7 1 8.7 
2 7.3 2 9. 1 2 7.6 
3 7.4 3 8.4 3 7.0 
4 6.9 4 8.3 4 7.2 
6 5. 1 6 8.5 6 8.2 
8 4.4 8 6.4 8 9.6 
12 2.8 12 6.5 12 10.6 
24 1 .0 24 1 .8 24 3.2 
27 1 .8 27 2.7 
33 0.5 33 1 .2 
Subject No. 23 
Male, 82.5kg, 20yr 
Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (llg/ml) (hr) (llg/ml) (hr) (llg/ml) 
0 3.3 0 5.2 0 6.7 
1 5.2 1 4.5 1 7.3 
2 6.3 2 4.6 2 7.0 
3 5.3 3 4.7 3 7.8 
4 5.5 4 5.2 4 6.6 
6 3.9 6 9.6 6 6.8 
8 3.1 8 8.5 8 6.2 
12 1 .8 12 6.5 12 4.8 
24 0.4 24 1 .7 24 1 .2 
27 1.0 27 0.9 
33 0.3 33 0.3 
166 
Table D12 
NONMEM Data Set· Study 1 
see Chapter Seven 
Subject No. 24 
Male, 81.6kg, 
20yr, Non-smoker 
Alcophyllin Elixir Euphyllin Retard Theodur 
Time Cp Time Cp Time Cp 
(hr) (v.g/ ml ) (hr) (v.g/ml ) (hr) (v.g/ ml ) 
0 6. 1 0 3. 1 0 9.6 
1 8. 1 1 3.5 1 11.0 
2 10. 1 2 4.0 2 10.9 
3 8.6 3 4.6 3 10.5 
4 8.5 4 5.0 4 9.8 
6 7.1 6 6.5 8 11 .0 
8 5.7 8 6.0 12 9.7 
12 5.4 12 5.6 24 4.6 
24 2.8 24 3.7 27 4.4 
27 2.9 33 3.3 












115 75.5 27 
64.5 
130 64.5 37 
63.7 
134 75 35 
47.6 
142 45.3 32 
47.6 
144 48.0 23 
145 64.0 21 
57.0 
146 60.3 21 
58.5 
150 48.0 27 
Table D13 
NONMEM Data Set - Study 2 
Patients 106 to 150 












F Euphyllin 6.78 13.0 
9.30 13.10 
F Theodur 9.30 15.00 
9.42 16.25 
F Euphyllin 6.83 12 
12.61 4.50 
M Theodur 8.80 15.00 
12.61 4.80 
M Theodur 12.50 5.00 
F Theodur 9.38 13.25 
10.53 12.00 
F Theodur 9.95 12.50 
10.26 12.75 





























151 64.9 32 
58.3 
158 61.5 31 
58.3 

















193 55.6 24 
204 77.5 30 
Table D14 
NONMEM Data Set - Study 2 
Patients 151 to 204 




F Theodur 9.25 11.50 
10.29 11.25 










F Euphyllin 11.75 15.17 
M 
Euphyllin 8.83 5.75 
Theodur 14.40 4.75 





7.19 11 .75 
7. 19 13 
































205 65.2 36 
219 54.5 36 





254 50.3 29 
281 60 28 
285 36.9 29 
287 49.2 29 
292 48 34 
Table 015 
NONMEM Data Set - Study 2 
Patients 205 to 292 




Theodur 9.2 11.75 
Euphyllin 7.86 7.5 
M 
Euphyllin 7.86 6.17 
Theodur 12.27 10.5 
F 
Theodur 11.01 5.5 
Theodur 11.01 5.67 
M Theodur 13.16 14.17 
F 
Euphyllin 11.14 14.75 
Euphyllin 11.91 14.75 
Euphyllin 10.18 13 
M Euphyllin 10.18 11.25 
Theodur 11.93 12.5 
M Theodur 10.0 10.17 
F 
Euphyllin 20.8 15.5 
Euphyllin 20.8 13.5 
M 
Euphyllin 10.41 19.0 
Theodur 12.2 9.5 
Euphyllin 10.67 10.5 
M Theodur 16.67 11.75 
Euphyllin 10.67 10.33 
170 
Cp 
Smoker 
(ug/ml) 
11.65 
8.41 
Yes 
10.0 
5.05 
11.0 
No 
11.55 
7.8 Yes 
10.31 
6.3 
No 
7.3 
7.6 Yes 
9.0 
9.13 Yes 
18.1 
23.03 
No 
2.4 
8.9 
Yes 
2.7 
9.4 No 
5.85 
